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Abstract
Neuronal cell death as a result of increased oxidative stress is involved in many 
neurodegenerative diseases including Alzheimer’s disease, Parkinson’s disease, stroke 
and ischemia. Bax is a well established pro-apoptotic protein o f the Bcl-2 family. It is 
critically involved in the initial phase of apoptosis under oxidative stress.
In this study we aimed to develop specific blockers against the pro-apoptotic Bax 
protein that would in turn block cell death. After screening a llama phage-display library 
for specific single domain antibodies (VhH) against purified recombinant Bax protein, we 
isolated six genes that code for VhH clones capable o f blocking Bax function in vitro 
(when expressed as antibodies) and in vivo (when expressed as intrabodies).
We have generated mammalian cell lines stably transfected with anti-bax intra­
body genes that are virtually resistant to apoptosis induced by oxidative stress. These 
genes and the protein coded by them are unique and specific biochemical tools with 
potential to inhibit proteins in their native structure. This is particularly advantageous for 
future biochemical mechanism studies to study the role of Bax in various cell death 
pathways. Specifically, these antibodies can be used to study the interaction of Bax 
protein to various other pro-and anti-apoptotic Bcl-2 family proteins. In addition, 
intrabodies have potential to be used either directly (as in gene therapy) or as models for 
the development of therapeutic agents, for disease involving cell death induced by 
oxidative stress.
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Chapter 1: Introduction
1.1 Apoptosis
Cell division, differentiation and death are important physiological processes 
which help control the number of cells in an organism (Raff, M, 1992). Until the last 25 
years the majority o f research has focused on the former two processes. However since 
this time, work on apoptosis has allowed for the various discoveries in understanding the 
importance o f  balance in cell number control for maintaining a healthy system (Kerr, J et 
al., 1972). Overall, apoptosis is understood to be vital for development and homeostasis 
in healthy organisms. Specifically, in development apoptosis is vital for proper organ 
and limb formation (Saunders, J, 1966), regulating cell numbers thus preventing 
uncontrolled growth (common to cancer) (Raff, M, 1992) and removal o f damaged and 
thus potentially harmful cellular debris (Cohen, J et al., 1992).
O f particular importance was the discovery that cell death in multicellular 
organisms was subject to genetic control (Ellis, H et al., 1986). Improper regulation of 
these genes was since been shown to result in inhibition of apoptosis resulting in various 
diseases such as cancer (Strasser, A et al., 1990) and autoimmune diseases (Watanabe- 
Fukunaga, R et al., 1992). However, inappropriate activation o f apoptotic pathways can 
have similarly detrimental effects as seen in various neurodegenerative diseases such as 
Alzheimer’s Disease (AD), Parkinson’s Disease (PD) and Stroke (Price, D, 1999). 
Research in understanding, elucidating and interfering with various apoptotic pathways 
has since grown exponentially, in an effort to combat these diseases.
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1.2 Apoptosis vs. Necrosis
Apoptosis is both physically and biochemically distinct from cellular death 
occurring by accidental damage also known as necrotic death. Necrotic death is a passive 
form of cell death which occurs from direct injury to a cell (Fig. 1.1 A). This results in the 
swelling and lysis o f the cell, followed by inflammation due to the release o f cytoplasmic 
material into the surrounding tissue (Steller, H, 1995; Pollack, M et al., 2001). 
Specifically, swelling occurs because the injury to the cell destroys the cells ability to 
control its fluid and ion balance, water and positively charged ions which are normally 
pumped out are allowed to enter the cell resulting in its rupture. In an effort to limit 
infection and clear cellular debris, macrophages and other white blood cells congregate at 
the rupture site resulting in inflammation which can have negative implications on 
surrounding tissues (Duke, R et al., 1996).
In contrast apoptosis is an active process divided into three unique phases: 
induction, effector and degradation/elimination phase (with distinct morphological 
features) (Fig. 1.IB). The induction phase may vary depending on the cell type involving 
a death inducing signal which may arise from within the cell or an external source. Some 
examples o f apoptosis inducers include reactive radicals (reactive oxygen species and 
nitrogen intermediates), tumor necrosis factor-a, activation o f Ca2+ pathway and 
upregulation or downregulation o f pro- and anti-apoptotic proteins respectively (Pollack, 
M et al., 2001). Despite the numerous activation pathways, the tight regulation of each 
pathway in healthy cells is a feature shared by all.
The second phase in the apoptotic pathway is the effector phase, where the cell 
becomes committed to die as key apoptotic pathways become activated including the
2
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extrinsic pathways via death domain activation on the cell surface (Baker, S et al., 1998) 
and intrinsic pathways involving the mitochondria (Kluck, R et al., 1997).
Theses events are subsequently followed by a degradation phase involving 
activation o f caspase cascades (cystein proteases) resulting in enzymatic cleavage o f 
cellular components. Plasma membrane flipping detected by the redistribution o f 
phosphatidyl serine between the inner and outer leaflet o f the plasma membrane is well 
studied feature o f apoptosis (Fadok, V et al., 1992). This is followed by changes at the 
nuclear level, specifically the breakdown o f the nuclear envelope and chromatin 
condensation while activated endonucleases fragment DNA (Kerr, J et al., 1972). In the 
last stages following these events apoptosis is characterized by unique morphological 
changes including plasma membrane blebbing, as the cell is fragmented into small 
apoptotic bodies, followed by phagocytosis by neighboring cells which prevents 
inflammation and damage to surrounding tissue (Pollack, M et al., 2001).
1.3 Apoptosis Pathways
Activation o f apoptosis involves tight regulation o f numerous pathways 
stimulated by both external and internal signals, resulting in extrinsic and intrinsic 
pathways.
1.3.1 Extrinsic Apoptosis Pathway: Receptor Mediated Apoptosis
Tumor necrosis factor superfamily (TNFR) receptors are a key component o f this 
apoptotic pathway. Two important ligands which can bind to these receptors are TNF-a 
and Fas ligand (FasL) (commonly present in immune cells). Binding o f these ligands to 
the cell membrane receptor results in activation o f a specific group of proteases
3
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m em brane  breakdown
Healthy Cell
Necrosis
Cell Swelling Cell Rupture
Figure 1.1 A Cell death through necrosis
Necrosis is a passive process occurring due to accidental cell injury resulting in cell rupture and 
inflammation.
Healthy Cell
Cell Fragmentation
(apoptotic body formation)
Apoptosis
intact membrane
nuclear fragmentation Phagocytosis of
apoptotic bodies
Figure 1.1B Cell death by apoptosis
Apoptosis is an active process in which the cell is signaled to dye by an external or internal signal. Upon 
activation of apoptosis nuclear condensation and fragmentation is noted followed by fragmentation of the 
entire cell into apoptotic bodies. Finally the apoptotic bodies are removed by phagocytosis from 
neighboring cells. In this process cell membrane is kept intact preventing cytosolic components from 
leaking into the outside and resulting in inflammation.
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responsible for the execution o f apoptosis (Baker, S et al., 1998). These proteins are 
more specifically known as caspases, a set of cysteine dependent, Asp-specific proteases 
which can function to activate other caspases (initiator caspases) or can be directly 
involved in cellular degradation (executioner caspases) (Lee, D, 2000). Receptor 
mediated induction o f apoptosis (shown in Fig 1.2) begins with the binding of FasL to the 
Fas receptor on the plasma membrane. This causes a conformational change in the Fas 
receptor leading to the, recruitment o f procaspase 8 to the cell membrane, by the Fas 
Associated Death Domain (FADD) bound to the Fas receptor. Procaspase 8 recruitment 
undergoes self activation resulting in the recruitment o f this protein and formation o f a 
death inducing signaling complex (DISC) at the plasma membrane (Salvesen, G et al., 
1999). Activated caspase 8 can then directly lead to executioner caspase 3 activation, 
which results in cleavage o f key proteins on the plasma and nuclear membrane leading to 
overall structural breakdown of the entire cell (Nicholson, D, 1999). In addition caspase 
8 has also been shown to mediate the cleavage and thus activation o f pro-apoptotic 
protein Bid, which exerts its apoptotic effect by facilitating mitochondrial membrane 
permealization in association with Bax (Desagher, S, 1999).
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Figure 1.2 Receptor mediated induction of apoptosis
Overview o f receptor mediated apoptosis resulting from FasL binding to Fas receptor and subsequent 
activation of initiator caspase 8 and executioner caspase 3 resulting in apoptosis of the cell.
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1.3.2 Intrinsic Apoptosis Pathway: Role of Mitochondria
Mitochondria are involved in many processes which are essential to cell survival, 
from energy production to redox control, in addition to maintaining a balance in various 
metabolic and biosynthetic pathways (Bouchier-Hayes, L et al., 2005). As the study of 
apoptosis has progressed, a great deal o f evidence has been presented placing the 
mitochondria at the heart o f apoptosis (Kerr, J et al., 1972; Cohen, J et al., 1992; Steller, 
H, 1995; Zamzami, N et al., 1995; Raff, M, 1996). The central event which leads to 
apoptosis involves the mitochondrial outer membrane permealization (MOMP) and 
subsequent leakage o f pro-apoptotic proteins from the inner membrane space (IMS) such 
as cytochrome c and apoptosis inducing factor (AIF). This process may occur as a 
consequence o f a number o f pro-apoptotic stimuli including activation o f pro-apoptotic 
proteins o f the Bcl-2 family such as Bid, Bak and Bax, inactivation o f anti-apoptotic 
proteins o f the Bcl-2 family such as Bcl-2 and B c 1-x l  and increased reactive oxygen 
species levels (Nomura, K et a l,  2000; Adhihetty, P et al., 2003)
The induction o f apoptosis through this pathway requires only a few mitochondria 
to be affected or for the membrane opening to occur transiently, resulting in release of 
pro-apoptotic proteins while still maintaining ATP synthesis. As previously discussed, 
apoptosis is an active process which requires ATP, therefore i f  MOMP occurs for a 
prolonged period o f time the mitochondria will uncouple and will be left unable to 
synthesize this molecule. To further complicate this situation, ATPase reverses direction 
and begins to actively hydrolyse cellular ATP, critically decreasing ATP levels. This 
leads to disruption of metabolic pathways and activation o f degradative enzymes 
(proteases, nucleases, phospholipases) resulting in cell swelling and rupture (necrotic
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death) and neighboring tissue damage. Therefore, the mitochondria play an important 
role in assessing cellular damage and inducing appropriate cell death (apoptosis). In 
cases o f extensive damage, which cannot be repaired, apoptosis is induced in order to 
prevent damage to surrounding tissue (Halestrap, A, 2002).
1.3.2.1 Molecular Mechanism of MOMP: Regulation by Bcl-2 Family of proteins
Currently there are two hypothesis presented which attempt to explain the 
principal behind MOMP regulation. In the first model, MOMP is understood as a process 
which is specific to only the mitochondrial outer membrane (MOM) and is regulated by 
the Bcl-2 pro- and anti-apoptotic proteins, which can promote or prevent pore formation, 
respectively (Fig. 1.3A). This evidence has been presented following studies which have 
shown that this family o f proteins is able to affect the permeability o f the (MOM) in cell 
free systems, by using vesicles formed from MOM. It has been proposed that pro- 
apoptotic proteins such as Bax and Bak may form a pore in the MOM either by homo or 
heterodimerization or activation by other BH3 proteins such as Bid, discussed above 
(Kuwana, T, et al., 2002).
Alternatively, the second model which attempts to explain the mechanism of 
mitochondrial destabilization and its role in apoptosis involves the formation of a 
permeability transition pore (PTP) (Fig. 1.3B). There are several components to the PTP, 
which span from the inner to the outer membrane o f the mitochondria. The voltage 
dependent anion channel (VDAC) protein is found to transverse the MOM while two 
other components cyclophilin D (cyp D) a soluble matrix protein and the adenine
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nucleotide translocase (ANT) protein are found on the mitochondrial inner membrane 
(MIM) (Halestrap, A, 2002).
The opening of the PTP (which leads to release o f cytochrome c and consequently 
apoptosis) is also under debate. Some evidence supports the idea that increased Ca 
levels can overwhelm the mitochondria and force the PTP into high conductance. This 
process is believed to be irreversible once the PTP is activated and is completely 
dependent on the saturation of all calcium binding sites o f the PTP (Ichas, F et al., 1998).
Other studies have shown that pro-apoptotic proteins such as Bax and Bak 
undergo translocation to VDAC from the cytosol upon activation 
(homo/heterodimerization or Bid activation) resulting in cytochrome c release (Murphy, 
K et al., 2000). In addition, both Bcl-2 (anti-apoptotic) and Bax have also been shown to 
interact with the MIM component, ANT to regulate cytochrome c release and apoptosis , 
as well as the MOM component, VDAC (Brenner, C, 2000).
Despite the debate over the role and mechanism o f the PTP in apoptosis, a great 
deal o f evidence has emerged in support o f the theory that the PTP facilitates the release 
of proapoptotic proteins and that the association o f Bcl-2 family o f proteins appear to 
play an important role in the PTP regulation.
9
R e p r o d u c e d  with p e r m is s io n  o f  t h e  co p y r ig h t  o w n e r .  F u r t h e r  r e p r o d u c t io n  p ro h ib i ted  w i th o u t  p e rm is s io n .
Cytochrome c-v 
(released) q
Cytoplasm Q  ^B ax /B ak  Pore
MOM
IMS
MIM
Matrix
O  Cytochrome c 
PTP (released)
i ? ° w
APAF-1
C aspase Activation
APOPT
Cytoplasm
MOM rupture
MOM
IMS
MIM
Matrix swelling—' Matrix
' 7 s
iii
■> H20  & ions
Figure 1.3 Molecular mechanism models of MOMP
The hypothesis presented suggest that pro-apoptotic proteins such as Bax and Bad play an important role in 
the leakage of MIM protein release. (A) In the first model Bax or Bak are thought to forms small pores 
only on the MOM. (B) The second model involves a permeability transition pore which found to more 
commonly associate with Bcl-2 family proteins to control its permeability and subsequently apoptosis.
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1.3.2.2 Consequences of MOMP
Despite the various causes of MOMP, in all cases this event most commonly 
results in release o f the IMS protein cytochrome c (normally functioning as vital 
component o f the electron transport chain) and ultimate cell death (Fig. 1.4). Once in the 
cytoplasm, cytochrome c binds to apoptotic activating factor-1 (APAF-1), an active 
process involving ATP. Subsequently, this association forces APAF-1 to undergo a 
conformational change exposing its caspase recruitment domain (CARD) resulting in the 
accumulation o f procaspase 9 which can undergo self activation. This initiator caspase is 
then able to activate (via proteolysis) executioner caspase 3 which in turn activates 
Caspase activated DNase leading to DNA fragmentation and ultimate cell death (Li, P et 
al., 1997). It should be noted however that cells may also express various caspase 
inhibitors, which may prevent apoptosis and act as death checkpoints for the cell. For 
example, one group o f proteins termed inhibitors o f apoptotic proteins (IAPs) contain 
both upstream and downstream inhibitory targets such as caspase 9 and caspase 3, 
respectively (Deveraux, Q, 1998).
In order to proceed with the apoptotic pathway, such inhibitors must be 
inactivated. This task is also accomplished by proteins released from the inner 
mitochondrial space (IMS) such as Smac (second mitochondrial derived activator o f 
caspases, DIABLO) which work to inactivate endogenous caspase inhibitors and AIF 
(apoptosis inducing factor) which migrates to the nucleus to induce chromatic changes 
(Green, D et al., 1998). These finding provide further insight into the tight regulation 
which is involved in the active process o f apoptosis as opposed to its passive necrosis 
counterpart.
11
R e p r o d u c e d  with p e r m is s io n  o f  t h e  co p y r ig h t  o w n e r .  F u r t h e r  r e p r o d u c t io n  p ro h ib i ted  w i th o u t  p e rm is s io n .
Apoptotic stimulir
C/Sr- ► w Q Cytochorome c
I—ATP
MitochondriaV*/ r
APAF-1
procaspase 9
APOPTO
Apoptosome Caspase 9
Executioner Caspase Activation 
(Caspase 3/7)
Figure 1.4 Effects of cytochrome c release from the mitochondrial IMS
Once cytochrome c is released from the mitochondrial inner membrane space, it forms a complex with the 
apoptosis activating factor which is responsible for the recruitment and activation of effector caspase 9. 
Subsequent activation of executioner caspases follows resulting in apoptosis of the cell.
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1.4 Bcl-2 Family Proteins
The growing family o f Bcl-2 proteins can be divided into two groups: anti- 
apoptotic such a Bcl-2, Bcl-xL, Bcl-w and pro-apoptotic such as Bax, Bak, Bcl-xS. 
These proteins share homology within 3-4 conserved regions termed Bcl-2 homology 
(BH1-4) domains and act as intracellular checkpoints in the cell death pathway 
(Korsmeyer, S et al., 1998). The presence and accessibility o f these domains strongly 
influences their apoptotic character. With a few exceptions mammalian anti-apoptotic 
proteins contain BH domains 1-4, while pro-apoptotic proteins generally contain BH 
domains 1-3 (Fig. 1.5).
These proteins play an important role in controlling mitochondrial permealization. 
Intracellularly, a balance exists between the pro- and anti-apoptotic Bcl-2 proteins and 
the ratio o f pro-apoptotic to anti-apoptotic is important for determining the susceptibility 
of a cell to apoptosis. In the event o f over-expression o f Bax (or similar pro-apoptotic 
members) apoptosis is accelerated, as noted in tissues where cell death occurs as part o f 
the normal maturation process (e.g. epidermis). In contrast, over-expression o f Bcl-2 (or 
similar anti-apoptotic members) leads to heterodimerization (with Bax) and repression of 
death induction (Oltvai, Z et al., 1993).
There are four Bax isoforms which result from alternative gene splicing o f box, 
including Bax a  (21kDa), p (24 kDa), y(5kDa), and 8(16kda) o f which only Bax a  and 
Bax P contain the BH3 domain necessary for induction o f apoptosis. O f these four 
isoforms, Bax a  has the necessary C-terminus transmembrane domain involved in 
permealization o f the mitochondrial membrane leading to apoptosis, and varies from the
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similar Bax P in the C-terminus (Oltvai, Z et al., 1993; Apte, S et al., 1995; Suzuki, M et 
al., 2000).
Yeast two hybrid work using various deletion mutants o f  Bax have proven that 
Bax uses its BH3 domain for homodimerization and heterodimerization with other 
members o f  Bcl-2 (pro- and anti-apoptotic), as mutation in only this region rendered the 
protein unable to dimerize. More specifically, Bax is understood to bind in a parallel 
(tail-to-tail) manner using this domain to itself and other Bcl-2 members. However, the 
apoptosis antagonists Bcl-2 proteins dimerize to each other using a head-to-tail 
conformation involving the BH4 domains o f one protein and the BH1 and BH2 domains 
of the second. In heterodimerizing with the pro-apoptotic partners, BH1 and BH2 
domains o f the anti-apoptotic protein interact with the BH3 domain o f  the pro-apoptotic 
partner (Zha, H et al., 1995).
In order to understand the whether the death promoter (Bax) resides upstream or 
downstream from the death antagonist (Bcl-2), in a genetic apoptosis pathway, knockout 
mouse models were utilized. From such work three models were proposed to account for 
the activity o f the Bcl-2 family proteins. Firstly, if  Bcl-2 acts as a prim ary suppressor o f 
apoptosis, its activity could be inhibited by upstream action o f Bax. Conversely, if  Bax 
acts as a downstream regulator o f death its homodimerization and subsequently activity 
could be quenched by upstream regulation o f Bcl-2. Lastly, both proteins have also been 
shown to act independently in the control o f  apoptosis despite the in vivo competition 
between these proteins (Rnudson, C et al., 1997).
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Figure 1.5 Selected Bcl-2 family proteins
With a few selected exceptions the anti-apoptotic group contains a unique BH4 domain absent in almost all 
pro-apoptotic members.
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There is some debate on the ability o f other members o f  the multigene family to 
substitute for missing Bcl-2 or Bax proteins using knock out studies. Studies using Bcl- 
2-/- knockout mice have shown a significant developmental defects as the majority o f 
newborn mice with this mutation die within a few weeks o f age (Veis, D et al., 1993), 
while those with mutations Bcl-x-/- result in embryonic death at approximately day 13 
(Motoyama N, et al., 1995). These results suggest that these anti-apoptotic proteins, are 
not interchangeable. Conversely, Bax-/- knockout mice studies by Lindsten et al. (2003) 
have demonstrated the complementary role o f Bax and Bak. Here, knock out in only one 
gene resulted in no obvious neurological phenotypic changes when compared to the 
doubly deficient mice, suggesting a possible a redundancy in the Bax and Bak protein 
role in apoptosis (Lindsten, T et al., 2003)
Further characterization has recently been published by Xin et al. 2006 showing 
the effects o f nicotine induced phosphorylation o f Bax at Ser (S) 184 by protein kinase 
AKT. This post-translational modification works to inactivate Bax specifically in lung 
cancer cells. Protein phosphatase 2A (PP2A) was found to be an active regulator in these 
cell types, working to both dephosphorylate Bax and also to break up the Bax-Bcl-2 
heterodimers allowing Bax to homodimerize and permealize the mitochondria inducing 
apoptosis (Xin, M et al., 2006).
1.5 Role of Reactive Oxygen Species (ROS) in Apoptosis
As previously discussed, apoptosis in dividing tissue is vital for the health o f an 
organism, as unnecessary, damaged or dangerous cells are replaced by newly formed 
healthy cells. However, inappropriate induction o f this cellular process can become
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equally detrimental, leading to loss o f healthy cells. When this occurs in post-mitotic 
tissue such as the brain which is composed o f specialized non-dividing cells (neurons), 
the overall function o f this organ can become seriously compromised as seen in multiple 
neurodegenerative disease such as Alzheimer’s disease (AD), Parkinson’s disease (PD) 
and stroke. Oxidative stress due to the production o f reactive oxygen species from the 
mitochondria is a persistent threat to mammalian cells.
Reactive oxygen species are oxygen containing molecules which possess unpaired 
electrons (free radicals), thus increasing their ability to react (bond) w ith other molecules. 
Biologically relevant free radicals include superoxide ion (02'*), perhydroxyl radical 
(H 02‘*), hydroxyl radical (*0H) which is the most reactive and least selective o f the 
radicals and the nitric oxide ion (NO*). Cellular toxicity due to reactive oxygen species 
arises from both direct reactions o f these molecules with biological targets (lipids, 
proteins, and DNA) and secondary reactions leading to formation o f  other radicals 
(Cuzzocrea, S et al., 2001).
Superoxide ion is among the most prevalent radical in biological systems, and is 
known to be formed by the enzyme NAD(P)H oxidase. As a means for coping with this 
threat, cells produce numerous anti-oxidant complexes (glutathione, uric acid and 
vitamins C & E) and enzymes (supersuperoxide dismutase (SOD), catalase and 
glutathione peroxidase). Specifically, the clearance o f superoxide radical is 
accomplished by the superoxide dismutase enzyme (SOD), converting 0 2'* into hydrogen 
peroxide (H20 2). Several enzymes such as catalase or glutathione peroxidase can then 
safely break down hydrogen peroxide into water, however in the presence o f reduced
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transition metals (ferrous ions), H2O2 can be converted into the reactive hydroxyl radical 
(•OH), contributing to the oxidative stress of an organism (Chance, B et al., 1979).
In addition to these anti-oxidant mechanisms, cells have also adapted to moderate 
levels of oxidative stress by involving ROS in common physiological functions: control 
o f ventilation, erythropoietin production and similar hypoxia-inducible functions, signal 
transduction and oxidative stress responses (Droge, W, 2002).
Despite the various coping mechanisms, in pathological cases leading to the 
aforementioned neurodegenerative diseases, an abnormal increase in reactive oxygen 
species overwhelms these protective measures resulting in often irreversible damage to 
tissues, as healthy cells become mistakenly apoptotic; a phenomenon commonly 
observed following reperfusion after ischemic stroke.
1.6 Neurodegenerative Disease and ROS
Neurodegenerative diseases affect the central nervous system (CNS) and include 
but are not limited to epilepsy, multiple sclerosis (MS), A lzheim er’s disease (AD), 
Parkinson’s disease (PD) and stroke. Though these diseases affect various tissues and 
also vary in course length and pathology, there are some important similarities. In all 
cases, one o f the primary reasons behind the detrimental effects o f  such diseases is the 
post-mitotic nature o f the cells (neurons) in the target tissue (CNS). Once injury to the 
CNS particularly in the brain has occurred, neurons which die cannot be replaced, leaving 
the patient with some type o f physical or mental functional limitation, depending on the 
specific area o f the brain which becomes affected (Price, D, 1999).
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Oxidative stress caused by elevated levels o f ROS in the brain is one o f  the major 
factors, particularly for AD, PD and stroke. In comparison to other organs, the brain is 
the most vulnerable organ to oxidative stress. This phenomenon is supported by the fact 
that brain cells make up approximately 2% of the total body mass but consume 20% o f 
the total oxygen intake as they rely almost solely on oxidative phosphorylation for ATP 
generation and thus generate larger quantities o f free radicals compared to other organs. 
In addition, certain brain regions contain high iron contractions which as mentioned 
above are able to catalyze free radical production. The brain is also rich in unsaturated 
lipids, which are an important target for lipid peroxidation and finally, the low 
antioxidant systems in the brain (compared to organs such as liver and kidney) offer 
minimal defense to elevated levels o f ROS (Dringen, R, 2000). As a result, minimizing 
and/or eliminating oxidative stress is immensely important in the development o f 
therapeutics against neurodegenerative diseases.
1.7 ROS role in Ischemia/Reperfusion Injury due to Stroke
Ischemic stroke in humans is the third most common cause o f death in most 
industrialized countries, after heart disease and cancer. Caused by an interruption o f 
blood flow to the brain, the effects o f stroke can range significantly depending on the 
particular region o f the brain which is affected. Functions such as memory, personality, 
cognition, language and motor skills can be either temporarily or permanently damaged, 
and in approximately 25% of cases patients are left in a vegetative state or die (Moore, R 
et al., 1993). In cases o f Stroke, neurons directly devoid o f blood flow, found in the core 
region of injury are killed within minutes o f this effect, while neurons in the surrounding
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region termed the penumbra retain their potential for survival for hours or even days. 
Specifically, this latter region can be saved by reperfusion when blood flow is returned, 
however, this is certainly not without consequences, discussed below (Schaller, B et al.,
2004).
Over the years three general treatment methods have been established, and used in 
combination for treatment o f stoke: eliminating the blood clot to restore blood flow, 
minimizing the recurrence o f clots through blood thinner drugs and most recently, 
neuroprotection though preventing the formation or scavenging free radicals formed as a 
result of reperfusion.
The primary aim in cases o f ischemic stoke is to eliminate the blood clot and 
restore essential nutrients carried by the blood to affected areas. Currently, physicians 
have several ways o f accomplishing this including thrombolytic recombinant tissue 
plasminogen activator (rTPA), which is effective in minimizing brain damage if 
administered within 3h of stroke onset. Unfortunately, many patients (especially the 
elderly) who suffer a stroke may not recognize the signs in this short period o f tim e and 
thus do not receive proper care. If left untreated for a greater period than 3h, despite the 
possibility o f spontaneous reperfusion, permanent and fatal brain damage will m ost likely 
occur. Recently two other dmgs with similar functions have also been introduced to help 
restore proper blood supply (reperfusion) to injured areas: pro-urokinase and intravenous 
ancrod containing fibrinogen lowering properties (Lee, J et al., 1999). The second 
category for treatment o f stroke is the use o f blood thinners which can minim ize the 
recurrence of clot formation to avoid stroke recurrence.
20
R e p r o d u c e d  with p e r m is s io n  o f  t h e  c o p y r ig h t  o w n e r .  F u r t h e r  r e p r o d u c t io n  p ro h ib i ted  w i th o u t  p e rm is s io n .
Therapeutic approaches based on reperfusion, although important for restoring 
much needed blood flow, consequently result in damage to surrounding and often healthy 
cells. After blood supply becomes available to neurons at the injury site, these cells often 
take up too much oxygen at one time leading to a drastic increase in free radical (ROS) 
production and oxidative stress which may spread to surrounding healthy cells. 
Subsequently, various pro-apoptotic proteins such as Bax become activated (in cells near 
the injury site but not directly affected by the stroke) leading to apoptosis o f post-mitotic 
cells. Such damage continues to occur up to 72 h after onset o f  stroke, and therefore, 
neuroprotection by preventing the production or eliminating free radicals has recently 
become an important target in therapeutic research (Rotham, S et al., 1986).
1.8 Intrabody Application in Therapeutics for Neurodegenerative Diseases
Intrabodies are antibody molecules which are expressed intracellularly, through 
gene transfection, in order to target specific cellular components. Such complexes are 
therapeutically relevant as they can lead to phenotypic knockout o f  a specific target 
within the cell (Kontermann RE, 2004). Since only the antigen binding site is required 
for activity o f intrabodies single chain Fv (scFv) which represent the smallest 
recombinant antigen binding fragment are among the most commonly applied. However, 
multiple other formats including Fab fragments, scFv-CK fusion proteins, single chain 
diabodies (V h-C h fragments) and most recently single domain antibodies ( V hH ) from 
camellid species have proven equally if  not more effective (Hudson, P, 1998).
Direct binding o f intrabodies to target proteins has been reported to either inhibit 
or activate these target proteins depending on their particular native function
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(Kontermann RE, 2004). For example, recent work on Parkinson’s Disease reported by 
Emadi et al. 2004, involved the use o f an anti-monomeric-a-synuclein scFv (intrabody) 
which binds to and prevents formation o f high molecular weight oligomers and 
aggregates o f this protein which are important characteristic features o f PD and other 
dementia related diseases (Emadi, S et al., 2004). Similar work was also reported by 
several other independent groups showing the decrease in these aggregation by specific 
intrabodies, for use in both understanding and treating this condition (Maguire-Zeiss, K et 
al., 2004; Zhou, C et al., 2004; Emadi, S et al., 2004).
Intrabodies have also been applied for the activation o f pro-apoptotic proteins 
such as caspase 3 as demonstrated by Tse et al. (2000), using a unique indirect approach. 
In this case, scFv-fusion protein consisting of an anti-P-galactosidase scFv fused to 
caspase 3 was able to lead to forced dimerization and thus autoactivation o f caspase 3, 
inducing apoptosis, when co-expressed with (3-galactosidase (Tse, E et al., 2000).
For the last number o f years, intrabodies have become a major focus in research 
o f therapeutics against numerous diseases in addition to those affecting 
neurodegeneration, including (but not limited to) cancer, targeting areas such as cell cycle 
regulation (Strubea, R et al., 2002) and anti-apoptotic proteins such as Bcl-2 (Piche, A et 
al., 1998). Intrabodies for treatment o f HIV-1 infections have also been introduced with 
targets such as viral coat proteins gpl20 (Chen, S et al., 1994) and gp41 (Zhou, P et al., 
1998) and transcription proteins cyclin T1 (Bai, J et al., 2003).
Although phenotypic knockout can be carried out using other methods such as 
RNA interference (iRNA) acting at the level o f mRNA and subsequent inhibition of 
protein synthesis, there are several advantages to using intrabodies for understanding
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cellular functions and developing therapeutic agents. Non-specific effects (binding 
alternate mRNA sites) are among the major safety concern in the use o f iRNA, which 
have imposed a blockade on numerous studies using this technology (Jackson, A et al.,
2004). Similarly, in 2004, Snove et al. reported that 75% of the 359 published siRNA 
sequences (at that time) posed a risk for eliciting non-specific responses, while 
Persengiev et al. further reported that by using a conventional 21-bp iRNA to treat cells, 
over 1000 genes involved in various and unrelated cellular functions were stimulated or 
repressed (Persengiev, S et al., 2004; Snove, O et al., 2004). This risk is reduced when 
using intrabodies, since binding does not occur simply through nucleotide base pairing, 
which can occur more readily in comparison to the interaction between an intrabody and 
their highly ordered protein targets.
Furthermore, when target complexes have multiple binding/interacting sites, 
repression o f the gene will lead to the alteration o f multiple functions, which may not 
necessarily be desired. However, by designing or screening only those intrabodies with 
the potential to bind to one specific site on multidomain targets, this problem can be 
eliminated, resulting in higher specificity o f the intrabody technology (Heng, B et al.,
2005).
In addition, to blocking various binding interactions, intrabodies can also be used 
to attach components such as localizing signals(to target complexes in order to relocate 
these other subcellular locations) or ubiquitin-proteosome pathway substrates (to targets 
for their selective degradation) (Cattaneo, A et al., 1999; Zhou, P et al., 2000).
Research into intrabody technology is a growing field, with important application 
potential in both academic and therapeutic discovery settings. Specifically, this
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technology can be applied for knock out studies at the protein level in  order to understand 
specific protein functions, without altering DNA. Furthermore, intrabodies can also be 
advantageous in treating diseases (such as cancer and HIV as discussed above) which 
result from genetic mutations leading to in specific protein mutations.
1.9 Single Domain Antibodies (VhH) as Potential Blockers for Pro-apoptotic Bax
Single domain antibodies are designed to contain only the active variable 
heavy region (V hH ). These antibodies (or intrabodies when expressed intracellularly) are 
derived from camellia or llama species which naturally lack the light chains expressed in 
conventional antibodies (Fig. 1.6). The absence o f the light chains allows researchers to 
isolate a smaller antigen binding active complexes termed single domain antibodies 
(sdAbs), which are at least half the size o f the scFvs isolated from conventional IgGs .
This smaller size is advantageous in structural studies, therapeutic application 
requiring tissue penetration, and recombinant antibody technology. In addition, when 
expressed as intrabodies the significantly smaller sdAb may prevent non-specific 
interactions and disturbances within the cell (Tanha, J et a l ,  2002). sdAbs also offer 
greater solubility than even heavy chain variable domains o f classic IgGs, which has been 
understood to occur due to the presence o f hydrophilic residues instead o f hydrophobic 
residues which are normally present between the light and heavy variable regions o f IgGs 
(Desmyter, A et al., 1996). The overall comparable affinity o f  sdAbs to conventional 
scFvs but higher solubility, stability and expression levels offers greater advantage for 
use in research at both mechanistic and therapeutic levels o f research.
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Antibody phage display libraries have been established from total RNA of naive 
llama lymphocytes, containing phages which display a specific sdAb on their surface and 
the gene for this sdAb. Through a panning technique a sdAb and its gene can be 
identified for almost any target antigen o f interest (Tanha, J et al., 2002). Obtaining the 
gene for the sdAb selected becomes immensely important as this can easily be transfected 
inside most cells to study the effects o f sdAb inside cells as intrabodies.
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scFvs
Conventional IgG Heavy chain sdAb
Vh H
(Human) (Llama)
0  Constant heavy chain
#  Constant light chain
#  Variable heavy chain
#  Variable light chain
Figure 1.6 Comparing single domain antibodies to conventional human antibodies
Unlike the conventional human antibodies, single domain antibodies (sdAbs) lack both sets of light chains; 
therefore the antigen combining sites are formed only from the variable heavy chain, (VhH).
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1.10 Objectives
Pro-apoptotic proteins such as Bax which can become activated during oxidative 
stress-induced apoptosis play a central role in death o f post-mitotic cells in 
neurodegenerative diseases. In order to prevent inappropriately induced apoptosis, we 
plan to use sdAb to inhibit the activity o f Bax.
The objectives o f this study are as follows:
1) To isolate and purify recombinant Bax protein from a culture o f transformed 
E.coli.
2) In collaboration with Dr.J.Tanha (NRC-IBS) to use a llama phage display library 
for a panning assay to isolate Bax specific VhH  clones by using immobilized 
recombinant.
3) To establish and standardize an in vitro assay for Bax activity on isolated 
mitochondria.
4) To functionally characterize the anti-Bax VhHs in vitro.
5) Finally, to express the anti-Bax VhH genes through transfection inside human 
neuroblastoma cells (SHSY-5Y) to study their efficacy in blocking oxidative 
stress induced apoptosis.
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Chapter 2: Materials & Instrumentation
2.1. Chemical and supplies
2.1.1. Cell Lines
Human Neuroblastoma (SH-SY5Y) cells and transformed kidney cells (Hek293) 
were purchased from the American Type Culture Collection (ATCC), Manassas, VA, 
USA.
2.1.2. Media
DMEM F I2 HAM was purchased from Sigma Chemical Company, Mississauga, 
ON, Canada. L-Glutamine, Gentamycin, Fetal bovine serum (FBS) and Geneticin were 
purchased from Gibco BRL, VWR, Mississauga, ON, Canada.
2.1.3. Other chemicals
Most of the chemicals including BSA, CHAPS, EDTA, EGTA, hydrogen 
peroxide, HRP, HEPES, MDA, MgCl2, Na2EDTA, TRIS-HC1, Triton X-100, 
parahydroxyphenylaceticacid (PHPA), succinate, thiobarbituric acid (TBA), 
trichloroacetic acid, trypsin, horse radish peroxidase-conjugated anti-mouse antibodies, 
monoclonal anti-green fluorescent protein, Bacto tryptone, Bacto yeast extract, lyzosyme, 
DNase, N iS04, imidazole and chlormphenicol were purchased from Sigma Chemical 
Company, Mississauga, ON, Canada.
DMSO, NaOH, NaCl, NaHC0 3  and sucrose were purchased from BDH Inc., 
Toronto, Canada. Glycine was purchased from EM Sciences, NJ, USA. Hoechst,
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Aimexin-V (red and green) were obtained from Molecular Probes, Eugene, OR, USA. 
Protein assay reagent, acrylamide, prestained gel standards and ammonium persulfate 
were purchased from Bio Rad, Ontario, Canada.
JC-1 kit, Dual Sensor: MitoCasp kits, Apo 3/7 HTS caspase assay kits were 
purchased from Cell Technology, Mountain View, CA, USA. Monoclonal anti­
cytochrome c IgGs and anti-Bax IgGs (for Western Blot) were purchased from Santa 
Cruz Biotechnology Inc, Santa Cruz, CA, USA. ChemiGlow West kit were obtained 
from Alpha Innotech Corporation, San Leonardo, CA, USA. Fugene 6 Transfection 
Reagent was purchased from Hoffmann-La Roche Ltd., Mississauga, ON, Canada.
2.2 Instrumentation
Fluorescent and phase contrast pictures were taken using a fluorescent microscope 
(Leica DM IRB, Germany). Fluorescence measurements were conducted in multiwell 
plate reader with the help o f Spectra Max Gemini XS (Molecular Devices, Sunnyvale, 
California). Absorbance was measured by a UV-Visible Spectrophotometer (Agilent 
Technologies). Absorbances in 96 well micro-titer plates were measured using a Bio-tek 
ELx 808ru Ultra Microplate Reader.
Cell culture was conducted under sterile conditions in the class-II type A/B3 
Biosafety cabinet (Nuaire), and all cultures were maintained in a CO2 incubator 
containing a HEPA filter (Thermo Forma). Centrifugation was done using low speed 
centrifuge (Jouan) and DESAGA (Sarstedt-Gruppe).
A pH Meter (VWR, Model 8100) with buffer solutions from VWR, an 
Adventurer ™ balance (OHAUS), Vortex Jr. Mixer from Scientific Industries Inc, 1296-
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002 DELFIA R plate shaker from Wallac, a heat block (Gibco BRL, VWR, Canada) 
Rocking platform model 200 from VWR, a Coming stirrer from Fisher Scientific 
(Toronto, Ontario), a Dounce homogenizer from Kontes Glass Company (NJ, USA), 
freezer vials (VWR) and Eppendorf pipettes (Fisher Scientific).
Dounce homogenizer was purchased from Kontes Glass Complany, NJ, USA. 
Cell culture supplies including culture dishes, flasks, pipettes, tubes, freezer vials were 
obtained from Sarstedt Inc, Montreal, Quebec, Canada.
Fluorescence microscope (Zeiss Axioskope 2 Mot plus, Gottingen, Germany) was 
used to monitor cellular staining (described in Methods) and fluorescence pictures were 
taken using a camera (Qlmaging, Gottingen, Germany). The images were processed 
using Improvision OpenTV v3.1.2, Jasc Paint Shop Pro v8.00 and Adobe Photoshop 
v8.0.
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Chapter 3: Methods
3.1 Isolation of Bax
3.1.1 Expression of Bax Protein
A culture o f E.coli transformed with box gene containing a His6 tag, (for 
purification purposes discussed below) was obtained from Bruno Antonsson. The culture 
was used to inoculate 100ml o f a 1L LB media stock (lOg Bacto tryptone, 5g Bacto yeast 
extract and lOg NaCl) supplemented with 20pg/ml Chlormphenicol. The flask was 
incubated overnight on a shaker at 37°C and then transferred to the remaining 900ml of 
LB stock and incubated on a shaker at 37°C. The culture was monitored using UV-Vis 
spectroscopy until it reached an absorbance o f approximately 0.5 OD2 8 0  at which point 
the expression o f Bax was induced using Arabinose (lg/L). The final culture was 
incubated overnight on a shaker at room temperature and the samples w ere then 
centrifuged at 20 OOOxg at 4°C for 15 min. The supernatant was discarded and the pellet 
was stored at -20°C for a maximum of 5 days before purification.
3.1.2 Purification of Bax Protein
The Bax expressing E.coli pellet described above was suspended in lysis/loading 
buffer (0.02 M Phosphate Buffer (Naf^PCL), lOOpg/ml Lysozyme, 50pg/ml DNase, 
2mM PMSF, 1% TritonXlOO, 0.05M Imidazole) and incubate over ice for 45min, 
followed by sonification at 4°C. Samples were then centrifuged at 20 OOOxg for lOm in at 
4°C and the supernatant containing protein fractions was collected and stored on ice. Bax 
was purified through affinity chromatography using Hi-Trap Nickel Chelating Column. 
The column was prepared by running 2.5ml o f 0.1M NiSCL solution, followed b y  20ml
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ddt^O  and lastly 30ml o f loading buffer at an elution rate o f 5ml/min. The protein 
solution was then loaded into the column at an elution rate o f 2ml/min, and Bax was 
bound to the column through the interaction of the His tag interaction with the stationary 
Ni2+ phase. Following this approximately 30ml o f loading buffer containing 0.05M 
imidazole (which can also interact with Ni2+ stationary phase) was also loaded and run 
through the column at the same elution rate to eliminate non- specific binding interaction 
which may have occurred between bacterial proteins and the stationary phase. This 
elution was collected in 5ml fractions whose protein estimation was determined using 
UV-Vis spectroscopy (described below), once the total protein concentration decreased 
and remained steady at low levels in the final fractions, it was assumed that the majority 
of non-specifically interacting proteins were removed. Bax was then allowed to elute out 
by loading elution buffer (0.02M Phosphate buffer and 0.5M Imidazole). The increased 
concentration o f imidazole allows for the displacement and release o f Bax which is 
collected and analyzed through SDS-PAGE and Western Blot (described below).
3.2 Protein Estimation
The concentration of proteins present in the total cell lysate sample was estimated 
using the protocol from BioRad Laboratories. The protein estimation was carried out by 
taking 2.5-5 pL aliquots o f each total cell lysate sample, 797.5-795 pL of water 
(respectively) and 200 pL o f BioRad protein assay reagent to a total volume of 1 mL in 
plastic cuvettes. The mixtures were vortexed and allowed to stand for 10 minutes at room 
temperature. The absorbance was then taken using a UV-Visible Spectrophotometer and
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analyzed at 595 ran. The standard curve was prepared by using various amounts of a 
standard protein solution (BSA) and recording the absorbance in identical condition.
3.3 Isolation of sdAb(VHHs) against recombinant Bax protein by panning a 
llama phage display library
The following work was carried out by Dr.J.Tanha and associates at the National 
Research Council o f Ottawa (Institute for Biological Sciences).
A llama VhH phage display library described previously was used in panning 
experiments (Tanha, J et al., 2002). Panning against recombinant Bax protein was 
performed as described by Tanha et al. 2002, with the following changes. In the second 
and the third rounds, the phage elution additionally involved M gC^/HCl treatment. First, 
the bound phages in the microtiter wells were eluted with 200 pi and neutralized with 100 
pi 1 M Tris-HCl pH 7.4. Then, the emptied wells were subsequently incubated with 100 
pi of 4 M MgCl2 at room temperature for 15 min. The eluted phage was removed and the 
wells were incubated with 100 pi of 100 mM HC1 for five min at room temperature. The 
MgC^/HCl-eluted phages were pooled, neutralized with 1.5 ml o f  1 M Tris-HCl pH 7.4 
and combined with the triethylamine-eluted phages. One ml o f the combined phages was 
used to infect E. coli for overnight phage amplification and the remaining 1 ml was stored 
at -80°C for future reference. VhH clones were identified from the titer plates by plaque- 
polymerase chain reaction and sequencing as described (Tanha, J et al., 2003). 
Following panning, phage clones from titer plates were amplified in microtiter wells and 
screened for binding to Bax protein by standard ELISAs using a horse radish
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peroxidase/anti-M13 monoclonal antibody conjugate (GE Healthcare, Baie d'Urfe, QC, 
Canada) as the detection reagent.
3.3.1 E. coli protein expression and purification of VhHs
V hH  genes were cloned from the phage vector into the expression vectors by 
standard cloning techniques. E. coli expression o f V hH s and subsequent purification by 
immobilized metal affinity chromatography were performed as described (Tanha, J et al., 
2003). Protein concentrations were determined by A28 0  measurements using molar 
absorption coefficients calculated for each protein (Tanha, J et al., 2002).
3.3.2 Preparation of sdAb (VhH) fusion constructs
V hH  genes were inserted in the Hind III/BamH I sites o f pEGFP-Nl (V hH -green 
fluorescent protein (GFP) fusion), pD sRedl-N l (VHH-red fluorescent protein (RFP) 
fusion) or Hind Ill/Not I site of pEGFP-Nl (V hH ) (BD Biosciences, Mississauga, ON, 
Canada). The VhH recombinant vectors were propagated in E. coli and were purified 
using QIAprep® Spin Miniprep kit according to the manufacturer’s instructions 
(QLAGEN, Mississauga, ON, Canada) by Dr.Tanha and associates in NRC-IBS Ottawa.
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3.4 Cell Culture
3.4.1 Propagation of Cell Lines
Human neuroblastoma (SHSY-5Y) cells and transformed human kidney cells 
(Hek 293) were grown in complete medium consisting o f DMEM H am ’s F12 media with 
the addition o f 2 mM L-glutamine and 10% (v/v) fetal bovine serum and 20 pg/ml 
gentamycin. Cells transfected for formation o f stable cell lines were also supplemented 
with 200 pg/ml Geneticin (G418). The cells were incubated at 37°C with 5% CO2 and 
95% humidity.
3.4.2 Cell line sub-culturing
Cells lines were grown in 25cm2 sterile flask and sub-cultured by removing the
culture medium through aspiration followed by the addition of 1ml o f  0.15% Trypsin and 
incubation for 1-2 min at 37°C until the cells were able to detach with minimal force 
from the flask wall. After this, approximately 4-6 ml o f fresh media was added to the cell 
solution and the cells were aliquoted in various culture dishes as needed.
3.4.3 Transfection of SHSY-5Y
Transfection o f mammalian SHSY-5Y cells with the purified anti-bax and control 
VhH plasmids (described above) was carried out using Fugene 6 Transfection Reagent 
(Hoffmann-La Roche Ltd., Mississauga, ON, Canada) following the manufacturer’s 
protocol. Briefly, under sterile condition in a laminar flow hood, 7 .5pi o f Fugene was 
added to lOOpl o f incomplete DMEM-F12 Ham media in a plastic eppendorff tube and
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left to stand for 10-15min. Approximately 4pg o f DNA was then added to this mixture 
followed by a second incubation in the hood for 30-40 min, after w hich the entire mixture 
was added to the cells (in completed medium). SHSY-5Y cells used for transfections 
were sub-cultured into 25cm2 flasks 24h prior to transfection for optim um  uptake o f the 
DNA. Forty eight hours after transfection, cells were transferred to complete DMEM 
media (as described above) containing 300 pg/ml Geneticin for selection o f positive 
transfected cells for 1-2 weeks. Stable cell lines were subsequently maintained in 
complete DMEM media as described above with 200 pg/ml Geneticin.
3.5 Preparation of post-nuclear cytoplasmic fraction
SHSY-5Y cells were grown to 70% confluence in 10-ml Petri dishes. The post- 
nuclear cytoplasmic fraction was obtained from these cells using a previously published 
method (Li, N et al., 2003; Naderi, J et a l, 2006). Specifically, cells were harvested by 
mechanical dislodging using a rubber policeman. Cells were then centrifuged at 500xg 
for 5 minutes. The supernatant was removed and the pellet was then washed twice with 
IX PBS pH 7.4 and centrifuged again at 500xg for 5 minutes. The supernatant was 
removed and the pellet was resuspended and incubated on ice in hypotonic buffer (lOmM 
EDTA, lOmM Hepes, 50mM Sucrose), followed by homogenization to rupture cell 
membranes. The homogenate was then centrifuged at 800xg at 4°C for 5min to separate 
the cytoplasmic (supernatant) and nuclear (pellet) fractions.
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3.6 Isolating Mitochondria
Post nuclear supernatant (described above) was collected and centrifuged at 
13000xg at 4°C for 10 min, and the pellet (crude mitochondrial fraction) was 
resuspended in isolation buffer (250mM Sucrose, lm M  MgCL, lOmM HEPES, 20mM 
Succinate) kept on ice and used within l-2h for experimentation.
3.7 Measurement of reactive ROS production from isolated mitochondria
Mitochondrial ROS generation is measured by H 2O2 generation rate, determined 
fluorimetrically by measurement o f the oxidation o f para-hydroxy phenyl acetate (PHPA) 
coupled to the reduction o f H2O2 by horseradish peroxidase (HRP), based on a  previously 
published protocol (Li, N et al., 2003; Naderi, J et al., 2006). Crude mitochondrial 
extract was suspended in isolation buffer (described above) with the addition o f PHPA 
(4mg/ml) and aliquoted evenly in a 96 well plate (~20pg/well) and incubated forming the 
following four fractions: (a) mitochondria alone (negative control), (b) mitochondria with 
Bax only (positive control), (c) mitochondria and one anti-Bax VhH (total o f six factions) 
and (d) mitochondria with Bax and one anti-Bax VhH (total o f  six factions). 
Approximately 2pg Bax and 4pg o f anti-Bax VhH was used. A total o f  0.4 units o f HRP 
was also added to each fraction and after 30 minutes o f incubation, the fluorescence o f 
oxidized PHPA (excitation 320 nm, emission 400 nm) was measured in a 96 well micro­
titer plate using the Spectra Max Gemini XS. Mitochondrial hydrogen peroxide 
production was determined by interpolation from the standard curve generated by reagent 
hydrogen peroxide. Total mitochondrial protein was estimated using BioRad with bovine 
serum albumin as a standard and the results were expressed per microgram o f protein.
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Microsoft Excel version 6.0 software was used for data representation and statistical 
analysis.
3.8 Cytochrome c release assay
Isolated mitochondria was divided into three equal fractions (60pg protein each) 
and incubate in three conditions: alone, with Bax (lpg ) and with Bax ( lp g )  and VhH 5-2 
(2p.g), for 20 min at room temperature, on a shaker. The samples were then centrifuged 
at 500xg for 10 min and the pellet and supernatant were resolved separately on SDS- 
PAGE, followed by Western Blot (described below) using monoclonal anti-cytochrome c 
as a primary antibody in a 1:500 dilution.
3.9 Western Blot Assay
All western blots were performed using the following protocol, w ith variations in 
the primary antibody as needed (monoclonal anti-Bax, monoclonal anti-cytochrome c, 
monoclonal anti-VDAC and monoclonal anti-green fluorescent protein). Protein samples 
from both in vitro and in vivo experiments were initially resolved using 10% or 12% 
SDS-PAGE technique, using 30-50pg o f sample per well. Gels were transferred onto a 
nitrocellulose membrane which was subsequently blocked using a non-fat milk solution 
(5% milk in TBST) for 45 min on a shaker at room temperature. The m embrane was then 
incubated with primary antibody o f choice at a dilution o f 1:500 in  2% non-fat milk 
solution, overnight at 4°C (12-18h). After this incubation period the membrane was 
washed with TBST three times and subsequently incubated with the secondary antibody 
(anti-mouse IgG (whole molecule) peroxidase conjugate) at a dilution o f  1:2000 in 2%
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milk solution and incubated at room temperature on a shaker. The blots were developed 
using a ChemiGlow West kit and recorded using an Alpha Innotech Corporation Imaging 
System.
3.10 Induction of Oxidative Stress
3.10.1 Hydrogen Peroxide Method
Working solutions o f H2O2 was made by diluting a 10 M stock o f H 2O2 solution 
with distilled water to a concentration o f 100 mM. SHSY-5Y cells were grown to 
approximately 70% confluence. Oxidative stress was induced by incubating the cells in 
complete media containing either 100 pM or 200 pM H 2O2 for 1 h at 37°C. The media 
was then replaced with fresh, complete media (without H2O2) and the cells were 
incubated for different time periods to monitor apoptotic features and oxidative stress 
parameters.
3.10.2 Hypoxia/Hypoglycemia
Cells grown between 50-70% confluence were placed in a oxygen free chamber in
control salt solution (llOm M  NaCl, 5.4mM KC1, 0.8mM MgCl2 , 1.8mM CaCh, 15mM 
NaHCCb 15mM HEPES, 50mM Glycine pH 8) for 12-24h at 37°C as needed. After this 
treatment, cells were removed from the chamber and the salt solution was replaced with 
fresh medium and cells were analyzed in 24h.
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3.10.3 Serum Deprivation
Cells were grown to 50-70% confluence in complete medium as described above.
Subsequently, the medium was replaced with DMEM-F12 Ham supplemented with only 
20 pg/ml gentamycin lacking both L-glutamine and FBS and observed for up to 72h.
3.11 Monitoring Apoptosis
3.11.1 Cellular Staining Techniques
3.11.1.1 Monitoring nuclear morphology
Nuclear morphology was monitored as an indicator for apoptosis in cells by 
staining cells with Hoechst 33342 to a final concentration o f 10 pM. A fter incubating for 
10 min at 37°C, the cells were then examined under a fluorescence microscope where 
brightly staining nuclear condensation was understood to indicate apoptotic cells. 
Fluorescence pictures were taken processed using Improvision OpenLab  v3.1.2, Jasc 
Paint Shop Pro v8.00 and Adobe Photoshop v8.0.
3.11.1.2 Monitoring mitochondrial membrane potential
Mitochondrial membrane potential was detected using JC-1 mitochondrial 
specific dye. The cells were treated with 10 pM JC-1 and incubated for 40 m in at 37°C, 
in dark. The cells were observed under the fluorescent microscope and fluorescence 
pictures were taken and processed as described above.
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3.11.1.3 Monitoring plasma membrane flipping
Annexin V was used to monitor plasma membrane flipping in cells according to 
manufacturers instructions. Briefly, Annexin V dye was added to Annexin-Binding 
Buffer (lOmM HEPES, 140mM NaCl and 2.5mM CaCl2 at pH 7.4) in a  1:2000 dilution 
and added to cells (following the aspiration o f original culture media). After incubating 
for 15 min at 37°C in dark, the cells were examined under the fluorescence microscope 
and fluorescence pictures were taken and processed as described above.
3.11.2 Monitoring Protease and ROS activity in vivo
3.11.2.1 Lipid peroxidation determination
Lipid peroxidation in cells was determined using the thiobarbituric acid-reactive 
substances (TBARS) reaction with malonaldehyde and related compounds as previously 
described (Cereser, C et al., 2001). Total cell lysates were extracted as described above 
and 10-25pl o f each fraction was incubated with 1ml of thiobarbituric acid on a 100°C 
heat block for 15 minutes, developing a yellow colour. After cooling, absorbance at 535 
nm was measured using a spectrophotometer. Lipid peroxidation levels were determined 
running internal standards o f malonaldehyde (MDA). Results were calculated per 
microgram of protein. Protein concentration was measured using the Bio Rad protein 
assay reagent with bovine serum albumin as a standard (mentioned earlier). Microsoft 
Excel 6.0 software was used for data representation and statistical analysis.
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3.11.2.2 Caspase 3/7 activation
The activation o f Caspase 3/7 was measured in cells using Apo 3/7 HTS ™  High 
Throughput Screen Assay kit (Cell Technology Inc, Mountain View, CA). Pre-cultures 
cells were trypsinized, collected and centrifuged at 500xg for 7 min at room temperature. 
Cell pellet was resuspended in 500pl PBS/ 2.5x106 cells and aliquoted into a black 96 
well plate as needed. To each fraction Caspase detection reagent (prepared as per 
manufacturers instructions) was added in a 1:1 dilution and plates were incubated at 37°C 
on a shaker for 45min. Measurements o f Caspase 3/7 activation w ere taken using a 
fluorescence plate reader at 488nm excitation and 520nm emission, and results were 
calculated as fluoresce per pg o f protein, where high values indicated caspase activation. 
Protein concentration was measured using the Bio Rad protein assay reagent with bovine 
serum albumin as a standard (mentioned earlier). Microsoft Excel 6.0 software was used 
for data representation and statistical analysis.
3.11.2.3 MitoCasp Assay for detecting general caspase activation and 
mitochondrial membrane potential
General caspase activation and mitochondrial membrane potential were detected 
in cells using a Dual Sensor: MitoCasp™ Assay Kit following manufacturers protocol 
(Farkass, D et al., 1989). Briefly, for both assays cells were harvested and suspended in 
PBS as described above. Cell suspensions from each o f each group (50-100pl) was 
transferred in a eppindorff tube and mixed with Caspase Reagent o r Mitochondrial 
Membrane Potential Dye (prepared as per manufacturers instructions). The final mixture 
was incubated at 37°C for 45min on a shaker. Cells were then centrifuged at 500xg for
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10 min at room temperature and the supernatant was removed. The pellet was washed 
with IX wash buffer provided in the assay kit, centrifuged at 500xg for 10 min at room 
temperature, followed by removal o f supernatant and repeating this step a second time. 
Cells were then resuspended in the wash buffer and transferred to a black 96 well plate 
for analysis by a fluorescence plate reader. Caspase activity was measured first, taking 
measurements at 488nm excitation and 520nm emission, followed by MMP activity 
measured at 549nm excitation and 574 emission. Results were calculated as fluoresce per 
pg of protein, where high values indicated caspase activation. Protein concentration was 
measured using the Bio Rad protein assay reagent with bovine serum albumin as a 
standard (mentioned earlier). Microsoft Excel 6.0 software was used for data 
representation and statistical analysis.
3.11.2.4 Immunoprecipitation
Immunoprecipitation was carried to detect the possible interaction of anti-Bax 
intrabodies with VDAC as described by (Adachi M et al., 2004), with the following 
changes. Mitochondrial fractions were extracted as described above for cells expressing 
VhH 5-2 and non-transfected SHSY-5Y. A solution o f 1 pi anti-VDAC monoclonal 
antibody with lOpl protein G-Sepharose beads was made in 300pl RIPA buffer (20mM 
Tris-OH, 150mM NaCl, lOmM KC1 and 1% triton X-100) and incubated for lh  at 4°C. 
Approximately 60pg of mitochondrial protein from each cell type was added to the pre­
incubated anti-VDAC solution described here, and both samples w ere incubated for ~18h 
at 4°C on a shaker. Immunoprecipitates were collected by centrifugation (500xg) for 2 
min at 4°C followed by washing the pellet three times using the RIPA  buffer. After the
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final wash the pellet was suspended in 30pl o f RIPA buffer and m ixed with lOpl o f SDS- 
sample buffer and the samples were analyzed using SDS-PAGE and Western Blot as 
described previously.
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Chapter 4: Results
4.1 Purification of Recombinant Bax for anti-Bax-sdAb (VhH) identification
In order to carry out a panning assay to identify sdAb (VhH) against the pro- 
apoptotic protein Bax, this antigen was isolated and purified from a culture o f E.coli cells 
transformed with bax containing a N-terminal polyhistidine-tag, as described in Chapter 
3, through affinity chromatography, using a Ni2+ chelating column. The presence o f the 
N-terminal polyhistidine-tagged protein allowed for the use o f a metal affinity resin as a 
method for purifying the recombinant Bax. The resin uses a tetradentate metal chelator 
to bind the Ni2+ ions by occupying four of the six coordination sites o f  the octahedral 
binding structure o f the metal ion. The remaining sites are left available for interactions 
with His tails o f recombinant Bax. Using low and high concentrations o f  imidazole 
which also has a potential to interacting with Ni2+ all non-specific proteins were eluted 
followed by release o f purified Bax, respectively.
Bax expression in E.coli following induction with Arabinose was monitored by 
SDS-PAGE, loading 20pg o f protein per well and stained with Coomasie Blue (Fig. 4.1). 
The supernatant and pellet fractions of induced cells (containing cytosolic and membrane 
bound proteins (S+ and P+) respectively) were compared to the supernatant and pellet 
fractions of non-induced cells (S- & P-, respectively). Highest Bax expression (detected 
by the ~21kDa band) was seen in the induced supernatant fraction (S+) as expected since 
Bax remains in the cytosol in its monomeric form.
Following purification, the pure Bax fraction was analyzed by SDS-PAGE to 
ensure additional (non-Bax) proteins (bands) were eliminated (Fig.4.2A). Bax is 
identified as the 40kDa band which was further confirmed using W estern Blot indicating
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that it was isolated in dimer form due to the presence o f non-ionic lipids such as Triton X 
used during the purification process, which force strong homodimer formation o f Bax 
(Hsu, Y-T et al., 1997) (Fig.4.2B). For this procedure the protein fraction was first 
resolved using SDS-PAGE, loading 20pg protein as above and transferred onto a 
nitrocellulose membrane. The membrane was probed with monoclonal anti-Bax IgG as 
the primary antibody (with recognition for the N-terminus o f Bax, common to isoforms a, 
8, and (3) in a 1:500 dilution in 2% non-fat milk solution. The blot was further probed 
with a secondary monoclonal anti-mouse HRP conjugate (1:2000 dilution) and developed 
using ChemiGlow West kit, showing a positive band at 40kDa for Bax. The experiment 
was subsequently repeated for each individual purification with similar results.
4.2 Panning a Llama phage display library for anti-Bax VhHs
Six anti-Bax recombinant VhH showing high affinity binding to recombinant Bax (with
intact His tag) and no binding to BSA as a control were obtained from Dr. Jamshid Tanha 
of the Institute for Biological Sciences, National Research Council o f Canada. The anti- 
Bax V hH s 1 to 5-2 were isolated by the processes o f panning described in Methods. 
They were tested for their affinity and specificity for Bax using ELISA and Biacore 
studies (data not shown).
4 .3  In vitro analysis of six unique anti-Bax V h H s  efficacy
The six unique anti-Bax VhHs identified in the panning assay were initially tested 
to understand if  binding o f Bax would translate in the inhibition o f its function. In order
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(MW std) S+ S- P+ P-
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29 kDa
209 kDa ___►
124 kDa -----►
80 kDa
20 kDa
Bax
Figure 4.1 Detection of Bax expression in induced vs. non-induced fractions
(A) Recombinant Bax expression was induced from a transformed E.coli culture. Following induction using 
Arabinose cells were collected and lysed through sonification to separate cytosolic proteins in the 
supernatant (S) and membrane bound proteins in the pellet (P). Superantant and pellet fractions from 
induced (+) and non-induced (-) cells were compared to detect Bax expression using SDS-PAGE and 
staining with Coomasie Blue. Higher expression of Bax was detected in the induced supernatant fraction 
(S+) compared to the non-induced supernatant (S-) by the noted ~21kDa band. Both the induced and non- 
induced pellet fractions (P+ and P- respectively) show less Bax expression as expected since this protein is 
cytosolic in its monomer form.
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Figure 4.2 Detection of Purified Bax through SDS-PAGE and Western Blot
(A) After isolation and purification from a transformed E.coli culture, the presence of purified Bax was 
confirmed using SDS-PAGE and staining with Coomasie Blue. Bax is isolated as a dimer at 40kDa 
following purification. (B) Purified Bax fractions were further anaylyzed through Western Blot using a 
monoclonal anti-Bax primary antibody which was detected after incubation with secondary anti-body 
((anti-mouse IgG (whole molecule) peroxidase conjugate) and developed using a ChemiGlow West kit.
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to investigate if  the anti-Bax V hH s could prevent the permealization o f the outer 
mitochondrial membrane, we monitored two parameters associated with Bax induced 
mitochondrial destabilization: elevation o f ROS production and release o f proteins from 
the mitochondria inner membrane space (IMS).
4.3.1 Anti-Bax V h H s  inhibit Bax-induced dysfunction of isolated mitochondria
Since there is no direct measure o f Bax activity on mitochondria, we chose to 
measure the ROS production by the mitochondria. Previous work in our laboratory has 
shown that in presence of isolated mitochondria, Bax is able to permealize the MOM and 
subsequently lead to increase in ROS production (Naderi, J et al., 2006). ROS is detected 
fluorimetrically by measurement o f the oxidation o f PHPA coupled to the reduction of 
H2O2 by horseradish peroxidase (HRP). Therefore, if  by binding to Bax the six anti-Bax 
VhHs were able to individually block its destructive effect on the mitochondria we would 
expect lowered fluorescence in those sample containing isolated mitochondria, Bax and 
anti-Bax VhH compared to controls o f mitochondria and Bax alone.
The data in figure 4.3 represents a compilation o f five independent experiments. 
In each individual experiment, the fluorescence detection for the negative control 
(mitochondrial alone) was subtracted from each subsequent fraction. In addition, the 
positive control fraction (mitochondria with Bax only) was taken as 100% fluorescence 
and all test samples (mitochondria, Bax and anti-Bax VhH clones) were calculated 
relative to this control. The results showed a decrease in ROS production in all fractions 
containing anti-Bax V hH s compared to the positive control (mitochondria and Bax 
alone). Anti-Bax 5-2 produced the most significant results, decreasing the fluorescence
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and thus the ROS production to approximately 10%, indicating strong protection o f  the 
mitochondria from Bax activity. Anti-Bax V hH s incubated with mitochondria (in 
absence o f Bax) did not affect the ROS level and even showed lower ROS generation that 
fractions containing mitochondria alone. This is possible since the anti-Bax VhH could 
be binding and inhibiting endogenous Bax isolated from mitochondria o f SHSY-5Y cells 
used, ha addition, in order to show that Bax binding and inhibition is not occurring due to 
non-specific interactions, a non-specific single domain antibody (raised against Caspase 
3) was also used as a control. This complex showed no consistent ability to prevent Bax 
induced mitochondrial destabilization. These results indicate that the anti-Bax VhH 
clones are binding and more importantly inhibiting Bax, by preventing specific Bax 
induced mitochondrial damage.
4.3.2 Anti-Bax VhHs prevent cytochrome c release from inner mitochondrial space
Another measurable consequence o f Bax-induced mitochondrial damage is the 
release of proteins from the mitochondrial inner membrane space (IMS). Since anti-Bax 
5-2 was able to strongly inhibit Bax induced ROS production form the mitochondria, we 
further tested its ability to prevent the release o f cytochrome c which normally resided in 
the IMS. As in the previous experiment, isolated mitochondria were divided into three 
equal fractions (60pg protein each) and incubated in three conditions: (a) mitochondria 
with reaction buffer only (b) with Bax (lpg ) alone, (c) with Bax ( lp g )  and V hH 5-2 
(2pg), for 20 min at room temperature. The fractions were then separated into 
supernatant fraction (containing proteins released from Bax-permealized mitochondria)
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■ With Bax 
□ Without Bax
M / B VHH (NS) VHH1 VHH2 VHH3 VHH4 VHH5-1 VHH5-2 
+ Bax
Figure 4.3 Measurement of ROS generation in isolated mitochondria (Mitoch)
Isolated mitochondria were incubated with Bax either in the presence or absence o f different VhHs in a 
reaction buffer. ROS generation was measured as described in Methods. ROS generated by Bax alone was 
taken as 100%. Different VhHs inhibited ROS production caused by Bax to different degrees with the best 
effect seen with Bax5-2 VhH. The standard error shown as error bars was calculated using Microsoft Excel 
program and the data obtained from five separate experiments.
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and pellet fractions (containing proteins retained in mitochondria). After resolving and 
analyzing these samples using (10%) SDS-PAGE and Western Blot, the presence o f anti- 
Bax VhH 5-2 reduced the amount o f cytochrome c released, by Bax destabilization o f  the 
MOM, compared to the positive control (mitochondria and Bax alone). These results 
were quantified by measuring the integrated density o f each band, which showed greatest 
cytochrome c release in fractions containing mitochondria and Bax, alone (Fig.4.4A). As 
expected, anti-Bax VhH 5-2 also increased the amount o f cytochrome c retained in the 
pellet fraction, shown in the Western Blot and the integrated band density graph. Equal 
protein loading was confirmed by Ponseau S staining o f the nitrocellulose membrane 
prior to blocking and incubation with the primary antibody (anti-cytochrome c IgG). All 
lanes showed similar intensity staining indicating equal protein loading and therefore 
eliminating the possibility that cytochrome c intensity changes in the developed Western 
Blots (Fig.4.4 A & B) are caused by greater starting concentrations o f  this protein (in a 
particular fraction). This further confirms the ability o f the anti-Bax V hH to not only 
bind Bax but also to prevent its interaction and destabilization o f the mitochondrial outer 
membrane, which can ultimately lead to apoptosis as described in Chapter 1.
4.4 In vivo analysis of six unique anti-Bax VhHs for preventing apoptosis
The in vitro functional characterization o f the anti-Bax VhHs are important 
positive preliminary results which suggest that these single domain antibodies can both 
bind Bax and inhibit its effect on isolated mitochondria. In the next phase o f this project, 
we set out to investigate the effect o f all six anti-Bax V hH s when expressed inside human 
neuroblastoma cells, SHSY-5Y. Specifically, we planned to investigate whether these
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Figure 4.4A Cytochrome c released in supernatant (protein released from m itochondria)
The fractions resolved by SDS-PAGE and further analyzed by Western blot represent cytochrome c 
released from the mitochondria. Lane 1 represents the negative control (mitochondria) showing low 
cytochrome c detection. Lane 2 represents the positive control fraction (mitochondria and Bax) showing 
the highest detection of cytochrome c, which is lowered when anti-Bax VhH 5-2 is present with Bax and 
mitochondria Lane 3. These results were further confirmed by generating integrated density values o f each 
band, with greatest cytochrome c release in the fraction containing mitochondria and Bax alone.
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Figure 4.4B Cytochrome c detected in pellet (protein retained in m itochondria)
The pellet fractions from the same experiment as described in Fig.4.4A, were subjected to the same 
analysis. Lane 1 represents negative control (mitochondria alone) which retains a large amount of 
cytochrome c. Lane 2 represents the positive control (mitochondria and Bax), showing a decrease in the 
retention of cytochrome c, indicating mitochondrial destabilization. Lane 3 contains mitochondria in 
presence of Bax and anti-Bax VhH 5-2, which also has similar retention detected as in mitochondria alone 
(lane 1), indicating that this VhH can inhibit Bax activity and limit mitochondrial permealization. The 
integrated density values for the bands shown also confirm that there was least amount of cytochrome c 
retention in fractions containing mitochondria and Bax alone.
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MW Pellet Fractions Supernatant Fractions 
Std nt/ntrf t/ntrf 5-2 nt/ntrf t/ntrf 5-2
209 kDa------►
124 kDa------►
80 kDa ► %
40 kDa------►
31 kDa------►
17 kDa ►
Figure 4.4C Ponseau S staining of Pellet and Supernatant Mitochondrial Fractions
To ensure that equal amount of protein were loaded in each lane for the detection of cytochrome c in the 
pellet (retained in IMS) or supernatant (released from IMS), the nitrocellulose membrane (onto which the 
gel was transferred) was stained with Ponseau S. Since the staining intensity in all fractions is relatively 
equal we can conclude that change in cytochrome c noted by the developed Western Blots (Fig. 4.4 A and 
B) were not attributed to overloading in a particular lane, but were due to the changes in cytochrome c 
localization within the cell.
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anti-Bax VhHs have the potential to prevent oxidative stress induced-apoptosis in this 
cell line. The anti-Bax VhH s were expressed inside this cell line through both transient 
and stable transfection using constructs containing the VhH gene obtained from Dr. 
Jamshid Tanha, NRC-IBS.____________
4.4.1 Transient Transfection of anti-Bax VhH plasmids in SHSY-5Y cells
Transient transfection was carried out as described in Methods, and positively transfected 
cells were confirmed through detection o f the RFP or GFP fluorescent marker protein, 
which were co-expressed with the VhH genes. Oxidative stress was induced within 24 h 
of the transfection by administering H2O2 to a final concentration o f  1 OOpM. The 
transfected cells were exposed for 1 h and qualitatively analyzed though cellular staining 
using Hoechst and JC-1 dye after 6h (data not shown) and 24h, to monitor nuclear 
morphology and mitochondrial membrane potential, respectively (Fig. 4.5). Cells 
expressing an anti-Bax VhH in fusion with GFP showed resistance to apoptosis under 
these oxidative stress conditions which have been shown in this and other studies in our 
laboratory to induce approximately 50% cell death (24 h after treatment) in SHSY-5 Y.
4.4.2 Stable Transfection of anti-Bax VhH plasmids in SHSY-5Y cells
Through transient transfection we were able to qualitatively show that the anti- 
Bax VhHs were able to reduce apoptosis due to H2 O2 induced oxidative stress. However, 
as transiently transfected cells make up only 5-10% of the cell culture in each plate, it 
becomes difficult to quantify these results. Therefore, the next phase in this project 
involved forming stable cell lines which express each o f the six anti-Bax VhH clones 
(individually) and monitoring their apoptotic resistance though cellular staining, protease
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VhH 5-1
VhH 5-2
Figure 4.5 Transiently transfected cells show resistance to oxidative stress induced apoptosis
The construct for each anti-Bax VhH in fusion with GFP or RFP (data not shown) was transiently 
transfected in SHSY-5Y cells. Oxidative stress was introduced by the addition of lOOpM H2C>2 for 1 h and 
cells were monitored after 24 h. Positively transfected cells, detected by presence o f GFP (column 1) 
generally show stable mitochondrial membrane potential confirmed by red punctuate JC-1 (column 2). 
Healthy nuclei are also seen in these cells through Hoechst staining (column 3). A brightly stained and 
apoptotic nuclei is detected for one of the cells transfected with VhH 4 (white arrows). Multiple apoptotic 
nuclei are detected among cells transfected with VhH 5-2, however these nuclei belong to non-transfected 
cells which are floating and not expressing the VhH 5-2 intrabody (yellow arrows) since they are not GFP 
positive.
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activation detection, ROS production (measuring ROS and monitoring lipid 
peroxidation). To ensure the specificity o f our anti-Bax V hH s , we also created three 
control stable cell lines expressing GFP or RFP fluorescent proteins (alone) and a non­
specific VhH (PTH5 0) fused with RFP.Stable cell lines were formed by taking advantage 
of the antibiotic resistance gene (Neor) therefore the addition o f  G418 allowed for the 
selection and propagation of positively transfected cells. By maintaining this antibiotic in 
the media at all times, the survival o f each cell depended on the presence o f the resistance 
gene (in fusion with the VhH gene) therefore this prevents the cell from removing the 
plasmid after 48-72h as occurs with transient transfection.
4.4.2.1 Confirming the expression of anti-Bax VhHs in stable cell lines
To ensure that cells in the newly formed stable cells lines are indeed expressing 
the specific anti-Bax V hH , we initially used the GFP or RFP fusion proteins as a maker 
for positive transfection. Since the VhH gene and GFP are expressed as fusion proteins 
cells which express the GFP or RFP must also express the VhH clones. Stable cell lines 
were therefore confirmed by detecting these fluorescent proteins through fluorescence 
microscopy (Fig. 4.6). The fluorescent protein markers were also useful to ensure that all 
non-transfected cells (no GFP/RFP expression) were eliminated by the G418 present in 
the culture medium. A culture o f non-transfected SHSY-5Y were also subjected to 
identical variations o f G418 (staring at 400pg/ml and gradually reduced to 200pg/ml) in 
parallel to the stable cell lines to ensure that non-transfected SHSY-5Y were not 
tolerating the antibiotic and becoming resistance during this time.
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Though the detection o f GFP or RFP fusion markers is a relatively facile way to 
verify that no non-transfected cells are present among our stable cell line, we also had to 
consider the possibility that the VhH gene can be excised, resulting in the sole expression 
of the marker protein (GFP or RFP) and not the anti-Bax V hH . We monitored the 
presence o f the intrabodies inside the SHSY-5Y cells through Western Blot, however one 
challenge for this experiment was the lack o f primary antibody for the unique anti-Bax 
VhH. Since the anti-Bax VhH clones were expressed in fusion with GFP, we were able 
to probe our Western blot with anti-GFP in order to detect the change in the molecular 
mass of marker protein, which would account for the presence o f the intrabody.
The anti-bax VhH  are approximately 10-12kDa therefore we expected to find the 
GFP band from each o f the six cell lines at a higher position than cells expressing GFP 
alone. Figure 4.7 confirmed these results as the band for each o f the six anti-Bax V hH 
appears approximately 10-12kDa ) above the control GFP only expressing cells, which 
accounts for the molecular weight o f the VhH clones (12kDa.
4.4.2.2 Cell viability following hypoxia/hypoglycemia induced stress
Hypoxia/hypoglycemia was induced in cells expressing anti-Bax intrabodies for 
12h (as described in Methods), after which point cells were rescued (placed in glucose 
media and exposed to oxygen) and monitored for signs o f apoptosis through nuclear 
morphology staining using Hoechst reagent to count cells to quantitatively determine cell 
viability (Fig.4.8). This experiment is a close model for studying damage caused by 
reperfusion, which occurs following a stroke. During the reperfusion phase o f stroke, 
there is a noted increase in reactive oxygen species which may spread to surrounding
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Figure 4.6 RFP expression
Following transfection of the anti-Bax VhH clones in fusion with RFP (shown here), cells were placed in 
complete medium containing G418 at a decreasing conentration (400pg/ml to 200pg/ml) for approximately 
two weeks, and after all non-transfected cells were eliminated (since they do not contain the G418 
resistance gene) cells were maintained in G418 media at 200pg/ml. The expression of RFP was used as a 
marker for the expression of anti-Bax VhH (3 and 5-2 shown here).
1 2 3 4 5 6 7
Figure 4.7 Confirming Expression of VhH by change in molecular weight of GFP
Western blot using anti-GFP primary antibody was used to detect the expression anti-Bax VhHs co­
expressed with GFP. Lanes 1-6 represent GFP detected from cell lysates o f stably transfected cells 
(expressing VhH 1 - 5-2 respectively) and lane 7 represents GFP detected in GFP only expressing cells (no 
VhH). Co-expression of all six anti-Bax VhHs (with GFP) was confirmed as the GFP band appears 
approximately 10-12kDa above the band for GFP only (lane 7), which accounts for the weight of the anti- 
Bax VhH clones (12kDa).
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healthy neurons causing over expression and activation o f Bax leading to inappropriately 
induced apoptosis o f these cells (Margaill, I et al., 2005). Therefore we monitored the 
ability of the anti-Bax intrabodies to inhibit Bax activity under similar conditions in order 
to prevent apoptosis. Following the induction o f hypoxia/hypoglycemia, Hoechst 
staining was used to count apoptotic vs. healthy nuclei, generating a cell viability graph. 
The variance in the cell viability rates o f cells transfected with the anti-Bax intrabodies 
and the non-transfected cells was found to be statistically significant (p<0.05). Therefore 
by inhibiting the pro-apoptotic function o f Bax the anti-Bax intrabodies were able to limit 
oxidative stress-induced apoptosis.
4.4.2.3 Caspase 3/7 activation is inhibited following hypoxia/hypoglycemia in cells
expressing VhH 5-2
Cells transfected with anti-bax intrabody 5-2 were also tested for their ability to 
prevent Caspase 3/7 activation (as previously described) following 
hypoxia/hypoglycemia treatment for 12h (Fig. 4.9). As expected, these cells exhibited 
low Caspase 3/7 activity (represented as fluorescence/p.g protein) comparable to the non- 
treated/non-transfected (nt/ntrf) control cells. Contrastingly, cells exposed to the same 
stress condition which were non-transfected (t/ntrf) exhibited higher Caspase 3/7 activity, 
suggesting that the anti-Bax intrabodies offer protection against apoptosis caused by 
oxidative damage.
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Figure 4.8 Hypoxia/Hypoglycemia induced oxidative stress inhibited by anti-Bax intrabodies
Following oxidative stress induced by hypoxia/hypoglycemia for 12h, cells were stained with Hoechst 
after 24h, and cell viability was determined by counting apoptotic and healthy nuclei. Cells expressing the 
anti-Bax intrabodies were able to overcome the damage caused by exposure to hypoxia/hypoglycemia, 
showing cell viabilities which were statistically different that the treated non-transfected cells (p<0.05).
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Figure 4.9 Caspase 3/7 remains iinactive in cells expressing VhH 5-2
Following hypoxia/hypoglycemia treatment for 12 h cells expressing anti-Bax intrabody 5-2 exhibit low 
caspase 3/7 activation almost identical to SHSY-5Y cells which were non-treated/non-transfected (nt/ntrf). 
Cells which do not express any intrabodies but underwent the same treatment (t/ntrf) show twice the level 
of Caspase 3/7 activation.
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4.4.2.4 Monitoring nuclear morphology following lOOpM H2O2 treatment
Stable cell lines containing each of the six anti-Bax VhH as well as four control 
cells lines (non-tranfected (ntrf), GFP only, RFP only and PTH50 (non-specific V hH ))  
were exposed to lOOpM H2 O2 for lh  and monitored after 24h for signs o f apoptosis 
through Hoechst staining to monitor nuclear condensation indicative o f  apoptotic nuclei 
(Fig. 4.10). The control cell lines (described above) which were exposed to the above 
treatment (t), showed poor resistance to apoptosis confirmed by numerous brightly 
stained nuclei. In addition, many of the cells in these samples were already detached and 
floating at this time point and not detected. Contrastingly, cells expressing any o f the 
anti-Bax VhH showed strong resistance to this stress factor as very few apoptotic nuclei 
can be detected.
Quantitative results for percent cell viability were attained by counting number of 
brightly stained, condensing nuclei compared to total nuclei using 5-10 fields from 3-5 
individual experiments (Fig. 4.11). In each experiment, the control and experimental cell 
lines were treated in parallel under the same conditions to ensure accuracy. Here control 
cell lines show a decrease in cell viability compared to non-treated SHSY-5Y (nt/ntrf) by 
approximately 50%. However, cells expressing the anti-Bax VhH s (in  fusion with GFP 
or RFP) show viabilities between 90-95%, after exposure to this stress level, which is 
comparable to non-transfected SHSY-5Y which were not treated (nt/ntrf), whose viability 
in culture is approximately 96%. Using statistical analysis the cell viability difference in 
cells expressing the anti-Bax intrabodies to all treated control cells (ntrf, GFP, RFP and 
PTH) were found to statistically significant (p<0.05). This indicated that the expression
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Figure 4.10 Nuclear morphology following lOOpM H20 2 treatment
Cells transfected with anti-Bax VhH and treated with lOOpM H20 2 for lh  (t/VHH (1- 5-2) were stained with 
Hoechst reagent after 24h, which showed a small percentage of apoptotic nuclei (bright staining) similar to 
the non-treated/non-transfected cells (nt/ntrf). In contrast a substantial increase in apoptotic nuclei is seen 
in all the positive control cell lines exposed to this treatment (t) including cells which were non-transfected 
(t/ntrf), and those transfected with GFP only (GFP), RFP (pDs-Red) and a non-specific VhH (PTH50).
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Figure 4.11 Quantifying cell viability following IOOjiM H2O 2 trea tm ent
Cell lines transfected with anti-Bax VhH were treated with oxidative stress (100 p.M H20 2 for 1 h). Non­
treated / non-transfected (nt/ntrf) cells were used as a negative control while all other control and 
experimental cell lines were exposed to the oxidative stress described. After 24 h cultures were stained 
with Hoechst reagent (as described in Fig. 4.8). Healthy and apoptotic nuclei from three separate 
experiments were counted using 6-10 fields/cell line/experiment, and the number o f healthy cells was 
plotted as a percentage of all the cells counted as Cell Viability. SHSY-5Y cells transfected with anti-Bax 
VhHs (fused with GFP or RFP) show strong resistance to apoptosis, with cell viability values which are 
statistically higher than all the treated control cell lines (p<0.05).
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of the anti-Bax intrabodies is not only non-toxic to these cells but is able to significantly 
reduce oxidative stress-induced apoptosis.
4.4.2.5 Monitoring plasma membrane flipping following lOOpM H 20 2 treatment
Control and experimental cells lines exposed to oxidative stress using lOOpM 
H20 2 for lh  were also monitored for a plasma membrane flipping through Annexin V 
binding 24 hours after treatment. Annexin V measures an early feature o f apoptosis: the 
phosphatidyl serine flipping across the plasma membrane. Annexin V green conjugate 
was used for cells expressing the anti-Bax intrabodies with RFP m arker proteins as well 
as for the RFP only control cell line. Annexin V red conjugate was used for experimental 
and control cell lines expressing the GFP marker protein. The four treated control cell 
lines (non-transfected, GFP, RFP, PTH50) all show substantial levels o f Annexin V 
binding (Fig. 4.12) which appears as a fluorescent outline o f cells in  the early phase of 
apoptosis.
In the experimental cell lines expressing anti-Bax intrabodies, there is limited 
Annexin V detected similar to non-treated/ non-transfected cells (Fig.4.13). Here the 
complimentary healthy nuclei are also shown through Hoechst staining, to confirm the 
presence o f numerous cells in the fields shown. Since protection against oxidative stress 
is limited in control cell lines, we can assume that the intrabodies alone are responsible 
for this action.
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Figure 4.12 Plasma membrane flipping in cells lacking anti-Bax VhHs
Control cell lines treated with lOOpM H20 2 for lh  show high levels of plasma membrane flipping through 
strong Annexin V binding. Cells transfected with the fusion protein alone (GFP or RFP) or a non-specific 
VhH (PTH50) behave as the non-transfected/treated cells (t/ntrf) indicating that no oxidative stress 
protection is offered by these complexes.
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Figure 4.13 Limited plasma membrane flipping detected in cells expressing anti-Bax VhHs
Cells transfected with any of the six anti-Bax VhHs were exposed to oxidative stress using lOOpM H20 2 
for lh  and monitored after 24h. These cells show limited Annexin V binding indicating that oxidative 
stress-induced apoptosis is inhibited due to the inhibition of Bax activity by the anti-Bax intrabodies. 
Complimentary nuclei images as also shown to confirm the presence of a large population of healthy cells 
in the respective fields. Overall, cells expressing anti-Bax intrabodies and exposed to the treatment behave 
similarly to non-treated/non-transfected cells (nt/ntrf). White arrows indicated apoptotic cells, yellow 
arrow shows a dividing nucleus and therefore it does not appear as Annexin positive.
67
R e p r o d u c e d  with p e r m is s io n  o f  t h e  co p y r ig h t  o w n e r .  F u r t h e r  r e p r o d u c t io n  p ro h ib i ted  w i th o u t  p e rm is s io n .
4.4.2.6 Monitoring mitochondrial membrane potential following lOOpM H2O2 
treatment
Control and anti-Bax VhH expressing cell lines were m onitored using JC-1 dye in 
order to measure the mitochondrial membrane potential (MMP) 24 hours after induction 
of oxidative stress using lOOpM H2O2 as described above. JC-1 is a  cationic dye which 
stains the mitochondria in healthy cells with a punctate red stain w hich is detected using 
fluorescence microscopy. Specifically, this lipophilic dye bears a delocalized positive 
charge which allows it to accumulate in healthy mitochondria (possessing an internal net 
negative charge), forming J-aggregates which fluoresce red. I f  the M M P collapses, JC-1 
cannot accumulate in the mitochondria and the dye remains in the cytosol as a monomer 
fluorescing a diffuse green. The green fluorescence is also seen in healthy mitochondria 
as some dye does remain in the cytosol at all times, therefore the true marker for 
detecting healthy vs. destabilized MMP is the presence o f red staining.
Cells expressing the anti-Bax intrabodies show healthy, punctuate red staining 
after the oxidative stress similar to the negative control cell line (non-treated/non- 
transfected) (Fig. 4.14). Hoechst staining was also shown in parallel here to confirm the 
total cells present in each field and also confirms that virtually all cells expressing anti- 
Bax intrabodies contain healthy MMP. These results agree with the earlier studies which 
looked at other apoptotic features such as nuclear fragmentation and plasma membrane 
flipping, showing that cells expressing anti-Bax intrabodies can tolerate oxidative stress 
(at the level o f lOOpM H2O2) and essentially behave as normal non-treated SHSY-5Y.
MMP was also monitored through a quantitative method using MitoCasp Assay 
Kit 6  hours after induction o f oxidative stress using lOOpM H2 O2 for lh , as described in
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Figure 4.14 Stable MMP detected through JC-1 staining in cells expressing anti-Bax intrabodies
Oxidative stress was induced by lOOpM H2O2 for lh  and after 24h cells expressing anti-Bax intrabodies 
(and control non/transfected cells) were stained with JC-1 which fluoresces red as it accumulated in healthy 
mitochondria. Healthy mitochondria are detected in the majority o f anti-Bax expressing cells, comparable 
to the non-treated/non-transfected cells.
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Methods. This assay also uses a cationic dye which accumulates in healthy mitochondria 
and can be detected using a fluorescence plate reader. The results o f  this experiment are 
shown as a measure o f fluorescence/pg o f protein (Fig. 4.15). Shown here, cells 
expressing VhH 5-2 behave like the negative control cell line (non-treated/non- 
transfected), fluorescing at almost double the intensity o f the treated/non-transfected 
cells. The difference in fluorescence indicating stable MMP, between the non-transfected 
treated cells compared to both the non-treated/non-transfected and the  treated/ V hH 5 -2  
transfected cells was found to be statistically significant (p<0.05). Therefore, these 
results suggest that by binding to Bax intracellularly, the anti-Bax intrabodies can prevent 
the permealization o f the mitochondrial membrane (leading to M M P collapse) both at 6  
and 24 h after treatment, thereby preventing apoptosis.
4.4.2.7 Caspase 3/7 activation is inhibited in cells expressing VhH 5-2
The activation o f executioner caspases 3/7 is one consequence o f Bax induced 
mitochondrial destabilization as described in Chapter 1. The activation o f these enzymes 
in cells expressing anti-Bax intrabody 5-2 was tested as described in  Methods using Apo 
3/7 HTS kit following the induction o f oxidative stress. Specifically, this assay uses a 
quenched (z-DEVD)2-R 1 10 peptide substrate. Active caspases 3 and 7 are able to cleave 
away the quenched dye R110 which can be detected fluorometrically when not 
complexed with the DEVD substrate.
For this study, cells were treated with lOOpM H 2O2 for lh  and tested following 6 h 
at which point sufficient caspase activation has been previously shown to occur, in our 
laboratory. The results were calculated as fluorescence / pg o f protein, and statistically
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Figure 4.15 Strong MMP detected in anti-Bax intrabody expressing cells following lOOpM H20 2
treatment
The MMP was monitored in cells 6h after exposure to oxidative stress using lOOpM H20 2 for lh, using 
MitoCasp Assay as described in Methods. In healthy mitochondria with stable MMP, the cationic dye used 
in this assay is able to aggregate and can be detected using a fluorescence plate reader. Non-transfected/ 
treated cells (t/ntrf) exhibited significantly lower fluorescence than the non-treated/non-transfected cells 
(nt/ntrf) and the treated VhH 5-2 expressing cells (p<0.05). This suggests that by binding and inhibiting 
Bax intracellularly, the anti-bax intrabodies can prevent MMP collapse induced by oxidative stress.
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analyzed to show that the treated/non-transfected (t/ntrf) cells exhibited significantly 
higher caspase 3/7 activation in comparison to the non-treated/non-transfected (nt/ntrf) 
cells and the treated/ VhH  5-2 expressing cells (p<0.05).
In addition general caspase activation was also analyzed in cells expressing the 
anti-Bax 5 intrabody using the Caspase detection component o f  the Dual Sensor: 
MitoCasp Assay kit previously described. This assay uses a novel approach to detect 
caspase activation, based in carboxyfluorescein (FAM) labled fluoremethyl ketone 
(FMK) peptide caspase inhibitor. These inhibitors are cell permeable and non-cytotoxic 
therefore they can easily bind to active caspases intracellularly and are measured using a 
fluorescence plate reader. The results are calculated as fluorescence / pg o f protein and 
show a statistically significant decrease (p<0.05) o f active Caspases 7-9 by approximately 
50% in VhH  5-2 transfected cells, compared to the treated / non-transfected control cells 
(t/ntrf) (Fig.4.17).
4.4.2.8 Low Levels of Lipid Peroxidation detected in cells expressing anti-Bax VhHs
Lipid peroxidation is an important marker for oxidative stress induced apoptosis.
Cells transfected with anti-Bax intrabodies were monitored for their ability to 
resist oxidative damage through the detection o f lipid peroxidation as described in 
Methods. Cells treated with lOOpM H2 O2 for lh  were tested after 24 h, compared to a 
negative and positive control (non-treated / non-transfected cells and treated/non- 
transfected cells respectively) (Fig.4.18). The results shown represent a compilation o f 5 
experiments, in which the lipid peroxidation was measured as pg M DA/pg protein. In
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Figure 4.16 Caspase 3/7 activation is inhibited by presence o f VhH 5-2
Cells expressing the anti-Bax intrabody 5-2 show significantly lower Caspase 3/7 activation compared to 
treated/non-transfected cells (t/ntrf) 6h after oxidative stress induced by lOOpM H20 2 for lh  (p<0.05). In 
this study was carried out using a Caspase 3/7 HTS Assay as described in Methods. In this assay an 
increase in fluorescence is indicative of caspases (3/7) activation, since these active proteases are able to 
release the quenched fluorescent dye linked to caspase substrate (DEVD). In fact the VhH 5-2 expressing 
cells behave similar to non-treated/non-transfected cells (nt/ntrf), as these two groups were not statistically 
different (p>0.05).
SH (nt/ntrf)
Figure 4.17 Caspase 7-9 activation inhibited in presence o f V hH 5-2
Caspase 7-9 activation was monitored in cells 6h after oxidative stress (lOOpM H20 2 for lh) using the 
Caspase component of the MitoCasp Assay. This assay fluorescently labled Caspase 7-9 inhibitors which 
accumulate in cells where these proteases are activated. Cells expressing the anti-Bax intrabody 5-2 show 
significantly lower Caspase 7-9 activation compared to non-transfected cells (t/ntrf) (p<0.05).
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each experiment, the value for the treated/non-transfected cells was taken as 100% and all 
other values were calculated with respect to this control and represented as a percent lipid 
peroxidation.
Cells expressing the anti-Bax intrabodies (and exposed to oxidative stress) 
showed limited lipid peroxidation comparable to the non-treated/non-transfected SHSY- 
5Y since the peroxidation levels o f these groups were not determined to be statistically 
different (p>0.05), further confirming the ability o f these intrabodies to prevent oxidative 
stress induced apoptosis, by inhibiting Bax function and its effect on the mitochondria, 
including the elevation of ROS.
4.4.2.8.1 Effect of anti-Bax intrabodies on cells treated with 200pM H2 O2
Cell lines expressing each of the six anti-Bax intrabodies showed strong 
resistance to apoptosis following oxidative stress induced by hypoxia/hypoglycemia 
(12h) and lOOpM H2 O2 (lh), which was not exhibited by any o f the control cell lines (to 
the same extent). However, using these levels o f oxidative stress, it was difficult to 
distinguish the most efficient intrabody; therefore cells were exposed to 200pM  H 2 O2 
(lh) treatment. Cells viabilities (Fig. 4.19) were calculated 24h after treatment, as 
previously described by counting healthy vs. apoptotic nuclei stained with Hoechst 
Reagent (Fig. 4.20). Non-treated/non-transfected SHSY-5Y (nt/ntrf) were once again 
used as a negative control, while all positive control and experiment cell lines (as 
previously described) were exposed to the treatment. In nt/ntrf cells a 96% viability was 
seen, which was close to the viability detected for cell lines expressing VhH 1,2,3 and 5-2 
(86%, 87%, 89% and 90% respectively). Cell lines expressing intrabody 4 and 5-1
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Figure 4.18 Lipid peroxidation reduced by anti-Bax intrabodies following lOOpM H20 2
treatment
Cells were treated using lOOpM H20 2 for lh  and monitored for lipid peroxidation following 24h. The 
presence of all six anti-Bax intrabodies significantly reduces the level of lipid peroxidation as these cells 
behave similar to the non-treated/non-transfected control SHSY-5Y (p>0.05, indicating no statistical 
difference between the nt/ntrf and all VhH expressing cells). Lipid peroxidation was not significantly 
reduced in cells expressing the non-specific VhH (PTH) in comparison to the t/ntrf cells (p>0.05).
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Figure 4.19 Cell viability detected following 200pM H 20 2
Cells expressing anti-Bax VhH show strong resistance to apoptosis. VhH 5-2 proved to be the most 
efficient at resisting this stress level, exhibiting 90% cell viability (96% shown for non-treated/non- 
transfected cells). VhH 4 and 5-1 (68% and 70% respectively) were least efficient of all the anti-Bax 
intrabodies at resisting apoptosis and yet still showed more promising results than all the positive control 
cell lines with viabilities less than 35%. The cell viability rate for all cells expressing anti-Bax intrabodies 
was found to be significantly higher when compared to each treated control (p<0.05).
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Figure 4.20 Nuclear morphology following 200p.M H20 2 (lh ) treatment
Cells expressing the anti-Bax intrabodies show only few apoptotic nuclei in each field shown following 
Hoechst staining 24h after oxidative stress (200pM H20 2 (lh)). Contrastingly the positive control cell 
lines (t/ntrf, t/GFP, t/PTH50) show a substantial proportion of apoptotic nuclei. At this time point many of 
these cells were floating (completely dead) and thus not visualized in the images selected.
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showed a decrease in viability (6 8 %, 70% respectively) however, this was still an 
improvement over the positive control cell lines. Cells which were not-transfected 
(t/ntrf) and those expressing only GFP (t/GFP), RFP (t/pDs-Red) or a non-specific 
intrabody (t/PTH50) showed poor cell viability rates (which were all significantly lower 
that the anti-Bax VhH expressing cells, p<0.05) following this extreme level oxidative 
stress (32%, 26%, 24%, 35% respectively). Interestingly, these results are in general 
agreement with the in vitro ROS data presented earlier, confirming that these specific 
anti-Bax intrabodies can bind and inhibit Bax activity, thereby protecting the 
mitochondria and cell death.
4.4.2.9 MMP following 200pM H2O2 treatment
JC-1 staining was also used to monitor the mitochondrial membrane potential in 
cells 24h after exposure to high levels o f oxidative stress using 200pM H 2 O 2 ( lh ) 
(Fig.4.21). As expected, cells expressing the anti-Bax intrabodies exhibited red 
fluorescence indicating the presence o f healthy, non-permealized mitochondria (VhH 1, 3 
and 5-2 shown here), similar to the non- treated /non-transfected control cells shown. 
Furthermore, non-transfected cells (which did undergo the described treatment) were not 
resistant to mitochondrial permealization and thus show no punctate red fluorescence. 
The respective nuclei for each JC-1 image are also shown to confirm the number o f  cells 
in each field and to show the healthy nuclei o f VhH transfected cells.
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Figure 4.21 Monitoring MMP through JC-1 staining
Following oxidative stress treatment using 200pM H2O2 (lh), red JC-1 aggregates are detected in cells 
expressing anti-Bax intrabodies (1, 3, 5-2 shown) indicating healthy mitochondria in these cells similar to 
the non-treated/non-transfected controls (nt/ntrf). In cells not expressing any VhHs, mitochondrial 
destabilization occurs after the described treatment an no punctuate red fluorescence is detected. 
Complimentary Hoechst pictures are also given, showing healthy nuclei in each field of anti-Bax 
expressing cells.
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4.4.2.10 Cells protected by anti-Bax VhH following 200pM H20 2 treatment
proliferate at a normal rate
Cells expressing the anti-Bax intrabodies showed strong resistance to apoptosis 
even after exposure to very high levels o f H20 2 (200pM), as shown through cellular 
staining techniques and low levels o f caspase activation. To ensure that this resistance 
was not at the expense o f various other cellular mechanisms (e.g. cell division), we 
monitored these cells following treatment for 10 days. Cells expressing anti-Bax 
intrabodies were treated with 200pM H20 2 (1), while non-transfected SHSY-5Y were 
treated with only 100 pM H20 2 (since no growth was detected following the higher level 
o f stress). After 48h the cells were trypsinized and counted using Trypan Blue (as 
described in Methods). This step was repeated after 5 and 10 days in order to record a 
growth curve for each cell line. All cell lines showed similar growth curves, and V hH 5 -2  
is shown in Figure 4.22, along with the growth curve for treated/non-transfected control 
cells.
Normally, SHSY-5Y populations double approximately every 48h, however the 
VhH expressing cells were not counted more frequently (e.g. every other day) since the 
growth may be negatively affected by the frequent exposure to trypsin. Cells expressing 
VhH 5-2 are shown to undergo just under two cycles o f division from day 5 to day 10, 
which is in general agreement with the doubling rate o f  untreated SHSY-5Y (Fig. 4.22). 
At this level o f oxidative stress, any surviving non-transfected SHSY-5Y at 24h after 
treatment did not survive following replating.
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4.4.2.11 Stable cell lines of ant-Bax VhHs in absence of marker proteins 
(GFP/RFP)
Stable cell lines using the anti-Bax VhH without the presence o f fluorescent 
proteins (GFP or RPF) were also created to ensure that the protective properties offered 
by these intrabodies were not caused by the possible interaction o f  the VhH with the 
marker proteins. We were able to successfully transfect and select all VhHs except VhH4 
due to a suspected problem with the antibiotic resistance gene. However, the remaining 
five stable cell lines expressing the anti-Bax intrabodies, showed strong resistance to 
200pM H2O2 (lh), and in the case o f VhH 5-1, we actually detected an increase in cell 
viability percentage proving that there is no advantage to the presence o f a marker protein 
(Fig. 4.23). The cell viability rates o f cells transfected in anti-Bax intrabodies alone, 
were significantly higher than all control treated cell lines (p<0.05).
4.4.2.12 Anti-Bax intrabodies show limited protection against serum 
deprivation
The specificity o f the anti-Bax intrabodies was tested by depriving cell 
(expressing the V hH s) from serum in the media. Serum derivation causes cell death due 
to the absence o f numerous essential growth factors required to sustain a healthy cell, 
which are not directly associated with the Bax associated apoptosis pathway. The 
specificity of the anti-Bax intrabodies to protect against only Bax associated apoptosis 
was tested by serum deprivation of the transfected cells. The cells were incubated in 
serum free media for 24h and 72h after which point nuclear morphology was monitored 
using Hoechst reagent (Fig.4.24). After 72h the transfected cells were undistinguishable
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Figure 4.22 Cell division is not affected following oxidative stress in cells expressing anti-Bax VhHs
Cell division was monitored by counting live cells (vs.dead dead cells) using Trypan Blue, starting at 24h 
after 200|iM H20 2 (lh) treatment in cells expressing the anti-Bax intrabodies (VhH  5-2 shown here). Cells 
expressing VhH 5-2 underwent just under two division cycles from 5d to lOd, which is in general 
agreement with the doubling rate of SHSY-5Y.
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Figure 4.23 Fusion proteins (GFP or RFP) do not offer advantage in protection from
oxidative stress
Cells transfected with anti-Bax VhHs without any fluorescent marker proteins showed strong resistance to 
apoptosis 24h after intense oxidative stress (200pM H20 2 for lh). In fact for V hH 5-1 we detected an 
increase in cell viability when the intrabody was expressed without a marker protein. Overall, the cell 
viability of VhH transfected cells was found to be significantly higher than all the control treated cells 
(p<0.05).
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from the treated/non-transfected cell lines (p>0.05). This indicated that the anti-Bax 
intrabodies exhibit their effect specifically on the Bax induced apoptosis pathway.
4.4.2.13 Preliminary investigation for the possible interaction between anti- 
Bax VhHs and VDAC
Since the anti-bax VhH studied here were able to protect the mitochondria from 
Bax associated permealization, we wanted to understand if  the intrabodies were possibly 
binding to Bax at its VDAC interaction site, thus preventing the Bax induced opening of 
the mitochondrial PTP. Using both V hH  5-2 expressing cells and non-transfected SHSY- 
5Y, we performed an immunoprecipitation using anti-VDAC antibodies and protein G- 
Sepharose-beads (as described in Methods). From previous work in our laboratory and 
other published works (Adachi M et al., 2004), Bax is understood to interact with VDAC 
and can be co-precipitated using anti-VDAC antibody attached to protein G-Sepharose 
resin. Using this information, we hypothesized that if  the anti-Bax intrabodies were 
interacting with Bax at the VDAC binding site, the presence o f the intrabodies would 
prevent Bax-VDAC interaction which can be monitored through immunoprecipitation 
followed by SDS-PAGE and Western Blot. After performing this experiment three 
times, a decrease in Bax was shown, for fractions extracted from cells expressing anti- 
Bax V hH s, compared to non-transfected SHSY-5Y fractions (Fig. 4.25). From this we 
suspect that the intrabodies may be preventing the Bax-VDAC interaction resulting in the 
inhibition of mitochondrial destabilization which has been shown in works throughout 
this study. However, since the ratio of anti-Bax V hH  to Bax expressed in the transfected
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Figure 4.24 Anti-Bax VhHs offer limited protection against serum  deprivation
The specificity of the anti-Bax intrabodies to only protect against Bax associated apoptosis (e.g. oxidative stress 
induced) was tested by depriving cells from serum. Cells expressing the VhHs showed no significant protection 
from this treatment after 72h indicating that their activity is Bax specific (p>0.05 at 72h for all VhH transfected 
cells compared to t/ntrf).
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cell lines is unknown, this experiment may provide more conclusive results if  we were to 
incubate a known quantity o f anti-Bax single domain antibody and recombinant Bax in 
presence o f  isolated mitochondria.
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Figure 4.25 Anti-Bax VhH 5-2 limits Bax -  VDAC interaction in  vivo
Bax proteins was co-precipitated with VDAC in cells expressing VhH 5-2 and non-transfected SHSY-5Y 
(SH(ntrf)) using anti-VDAC linked to Proten G-Sepharose beads and resolved using SDS-PAGE and 
Western Blot. Approximately 60pg of mitochondrial protein loaded for each fraction and the blot was 
probed with monoclonal anti-Bax primary antibody. In mitochondrial fractions isolated from cells 
expressing VhH 5-2, a decrease in Bax co-precipitation was seen (compared to non-transfected fractions) 
indicating that the intrabodies may be protecting the mitochondria from permealization by preventing the 
interaction o f Bax and VDAC, which are associated with the permealization of the outer mitochondrial 
membrane and subsequent damage to this organelle.
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Chapter 5: Discussion
In this study we have identified six unique single domain ( V hH )  antibodies 
against the pro-apoptotic protein Bax. When expressed intracellularly these intrabodies 
did not show any toxicity to the host cells, and rendered the cells resistant to damage 
from intense oxidative stress, by blocking Bax function. These intrabodies were able to 
protect cells from oxidative stress induced-apoptosis by inhibiting a key protein in this 
pathway, Bax. Therefore, the anti-Bax intrabodies have important potential as models for 
identifying chemical blockers which can mimic the action o f the V h H s described here, 
for possible treatment o f neurodegenerative diseases which involve Bax associated 
oxidative stress induced-cell death.
5.1 Targeting Bax as a means to inhibit oxidative stress induced apoptosis
In order to prevent oxidative stress induced-cell death in post-mitotic cells, we 
chose to target Bax protein due to its central role and its ability to behave as a check point 
in this cell death pathway (Korsmeyer, S et al., 1998). Specifically, Bax is understood to 
translocate from the cytosol to the MOM where it likely associates with VDAC a 
component o f the mitochondrial permeability transition pore, causing the opening o f the 
mitochondrial outer membrane (MOM) and release o f various pro-apoptotic proteins such 
as cytochrome c, which lead to subsequent cell death. Bax is understood to play an early 
role in the intrinsic apoptosis pathway and thus an important target for efficiently 
inhibiting this process in post-mitotic cells.
The increase in Bax activity in the presence o f reactive oxygen species also makes 
this protein a valuable target for elucidating treatments for neurodegenerative diseases,
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which involve inappropriate induction of apoptosis due to oxidative damage. 
Specifically, over-expression of Bax is shown in several neurodegenerative diseases such 
as stroke and Alzheimer’s Disease (AD). Specifically, the Bax associated intrinsic 
apoptosis pathway has been directly linked to neuronal cell death following 
ischemia/reperfusion injury. Furthermore, by inhibiting Bax function (in vitro) using Bax 
blockers such as the anti-apoptotic drug furosemide, neuronal cell death was shown to be 
significantly reduced (Chi-Hsin, L et al., 2005). In addition, elevated levels o f Bax have 
also been shown to co-localize with amyloid-beta plaques, w hich are believed to 
contribute to AD progression and neuronal cell death through an apoptotic mechanism 
involving Bax (MacGibbon, G et al., 1997). Therefore, the central role o f Bax in the 
induction o f neuronal cell death makes it an important target for protecting these post­
mitotic cells from apoptosis in the treatment o f neurodegenerative diseases.
5.2 Using single domain antibodies to inhibit Bax activity
Single domain antibodies ( V hH )  are derived from llama species which possess 
only heavy chain antibodies. These antibodies are particularly advantageous for in vivo 
studies, compared to small antibody fragments derived from conventional human IgGs 
(scFvs), due to their smaller size and greater solubility. By isolating and amplifying only 
the specific antigen binding regions, we can select low m olecular weight peptide 
fragment with very specific and strong binding affinities for an antigen o f interest, such 
as Bax. In a llama phage display library, the specific antibody gene against almost any 
potential antigen (isolated from the genome o f naive llama lymphocytes) is individually 
cloned into a phage which expresses the anti-body o f choice on its surface. Therefore
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through a panning assay we can both isolate the specific VhH for any antigen and more 
importantly its gene. Overall, through a panning technique we have isolated six unique 
single domain antibodies and their genes. This allowed us to study these sdAbs in 
various ways: in vitro to test their efficacy at preventing Bax induced mitochondrial 
permealization and in vivo through transfection, thereby expressing the VhHs as 
intrabodies to ensure that they can prevent oxidative stress induced apoptosis while 
remaining non-toxic to the host cell.
5.3 Specificity and efficacy of anti-Bax VhHs in preventing Bax function
Though the exact mechanism o f Bax induced mitochondrial membrane 
permealization is still debated, it is well documented that the presence o f Bax does indeed 
cause mitochondrial membrane potential (MMP) collapse resulting in generation and 
release o f more ROS and other pro-apoptotic proteins such as cytochrome c (from the 
inner membrane space (IMS)) (Korsmeyer, S et al., 1998; Brenner, C, 2000; Halestrap, 
A, 2002; Adachi M et al., 2004). By incubating isolated mitochondria in presence of 
anti-Bax VhHs and Bax, we have shown the ability o f these antibodies to protect the 
mitochondria by both decreasing ROS generation and limiting the release o f  cytochrome 
c from the IMS. When incubated with mitochondria alone (in absence o f Bax) the anti- 
Bax V hH s showed even lower ROS production than fractions containing mitochondria in 
buffer (in absence o f Bax and sdAbs). This suggests that the anti-Bax V hH s are possibly 
inhibiting endogenous Bax expressed in SHSY-5Y which may be present in the isolated 
mitochondrial fraction. A decrease in ROS was not detected in fractions containing a 
non-specific single domain antibody (raised against caspase 3), indicating that the anti-
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Bax sdAbs were able to both bind to Bax and more importantly inhibits its destructive 
function on  the mitochondria. Since, Bax induced MOMP was limited in presence of 
anti-Bax V hHs, it is likely that these antibodies may be interacting with the 
transmembrane (a 9) region o f Bax and thereby preventing its interaction with the MOM 
which can lead to elevation in ROS production and increased cytochrome c release.
By using a llama phage display library we were able to select six sdAbs and their 
respective genes. By inserting each of the genes into a mammalian expression vector, we 
were able to analyze the activity o f the antibodies inside pre-neuronal cells through 
transient and stable transfection. This investigation was particularly important since the 
intracellular environment is substantially different than working in the more controlled in 
vitro conditions.
Transient transfection o f each of the six VhHs provided important results showing 
the potential o f the V hH s to block Bax activity and apoptosis due to oxidative stress. 
After treatment with lOOpM H2O2 (lh), which was shown to induce approximately 50% 
cell death in non-transfected SHSY-5Y, positively transfected cells showed good 
resistance to this treatment. This was indicated by both Hoechst staining (showing 
healthy, non-condensed nuclei) and JC-1 staining (showing strong red fluorescence 
indicative o f healthy mitochondrial membrane potential).
Although we were encouraged by the findings o f the transient transfection work, 
in order to provide more conclusive and quantified results we created stable cell lines 
expressing each o f the six anti-Bax VhHs and three control stable cell lines expressing 
the fluorescent marker proteins (GFP and RFP alone) and a non-specific V hH (PTH50).
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Cells expressing the anti-Bax V hH s showed strong apoptosis resistance when 
exposed to various levels o f oxidative stress, including hypoxia/hypoglycemia (12h), 
lOOpM and 200pM H2 O2 (lh ) treatments. These results were in general agreement with 
the in vitro ROS results, with the exception o f anti-Bax VhH 1 and 2 which were not as 
efficient at decreasing ROS production, but still showed comparable cell viabilities when 
expressed in vivo. This is not very surprising since the extracellular and intracellular 
environments are quite distinct. Specifically, it is possible that when expressed in the 
mammalian neuroblastoma cells, intrabodies 1 and 2 may experience some 
conformational modification in their quaternary structure increasing their ability to bind 
Bax. In addition, although anti-Bax VhH 1 and 2 may bind Bax less efficiently in vitro, it 
is possible that these intrabodies may be weakly interacting with multiple pro-apoptotic 
Bcl-2 proteins (e.g. Bax and Bak), rendering their host cells more resistant to apoptosis. 
Alternatively, the Bax binding efficacy o f intrabodies 3 and 5-2 can be slightly reduced in 
vivo due to interference o f various cytosolic proteins, thereby resulting in cell viability 
rates comparable to the less efficient anti-Bax VhH 1 and 2. Anti-Bax VhH 4 and 5-1 
exhibited lower poteintial for Bax inhibition in both environments as demonstrated by 
higher ROS production and lower cell viability (compared to the remaining four anti-Bax 
VhH clones) in vitro and in vivo, respectively.
Following these treatments, the nuclei o f anti-Bax VhH transfected cells showed 
few brightly stained condensing nuclei (indicating apoptotic cells) even after the harsh 
200pM H2 O2 treatment, with VhH 1,2,3 and 5-2 exhibiting cell viabilities close to non- 
treated/non-transfected cells. In contrast, the control cell lines showed poor cell viability
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rates under the same conditions, indicating that the protection offered by the anti-Bax 
intrabodies did not result from non-specific interactions.
These results were further confirmed using other cellular staining techniques 
including Annexin V and JC-1. Annexin V is a specific marker for early phase apoptosis, 
which measures plasma membrane flipping. Specifically Annexin V binds to 
phosphatidyl serine complexes which translocate from the inner to the outer leaflet o f  the 
plasma membrane, and are detected by a fluorescent ring formation around cells in early 
phase apoptosis. Limited Annexin V binding was detected in cells expressing the anti- 
Bax intrabodies, exposed to oxidative stress (lOOpM H2O2 (lh)), unlike the control cell 
lines which exhibited strong Annexin V binding after the above treatment.
JC-1 staining was also used to confirm the positive effect o f  the anti-Bax 
intrabodies following oxidative stress (lOOpM and 200pM H 2O2 (lh )), by monitoring the 
mitochondrial membrane potential (MMP) o f the experimental and control cell lines. In 
healthy cells, JC-1 aggregates in the mitochondria and fluoresces red, while the dye 
remaining in the more dilute cytosol environment fluoresces green. In apoptotic cells, 
where the mitochondria have been damaged, JC-1 cannot accumulate in this organelle 
and thus remains in the cytosol where only the diffuse green fluorescence is detected. As 
expected, cells expressing the anti-Bax intrabodies exhibited healthy mitochondria 
indicated by strong red fluorescence, not detected in treated/non-transfected cell lines.
In addition, caspase activation a downstream consequence o f  mitochondrial 
destabilization was also shown to be inhibited in cells expressing anti-Bax intrabodies. 
Low levels o f activation o f both executioner caspases (8 and 9) and executioner caspases 
(3 and 7) were shown in the anti-Bax VhH expressing cells, after oxidative stress (lOOpM
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H2O2 (lh) o r hypoxia/hypoglycemia (12h)), while control non-transfected cells showed a 
doubling o f  the activation levels o f both types o f caspases after the same treatments.
Furthermore, we have also been able to show that the protection from oxidative 
stress offered to cells was solely due to the presence o f the specific anti-Bax V hH s. This 
was proven by showing that cells expressing only fluorescent proteins (GFP or RFP) or a 
non-specific VhH (PTH5o) showed poor survival rates following oxidative stress which 
had little effect on the anti-Bax V hH  transfected cells. Finally, w hen stable cell lines 
were formed without the fluorescent marker proteins, the cell viability rates remained 
high and even increased for cells expressing VhH 5-1, which indicated that only the anti- 
Bax VhHs are responsible for the resistance to oxidative damage, both in vivo and in 
vitro.
5.4 Anti-Bax VhH are specific inhibitors of the Bax associated apoptosis pathway
The specificity o f the anti-Bax intrabodies against Bax associated apoptosis was 
tested using serum deprivation treatment for up to 72h. Cells transfected with anti-Bax 
intrabodies showed resistance to apoptosis after 24h, however this protective effect was 
decreased significantly after 72h, at which point the anti-bax V hH s were rendered 
ineffective. The minimal protection offered by the anti-Bax intrabodies can be explained 
since the mechanism o f serum deprivation induced cell death is not completely Bax 
dependent.
Although the exact mechanism leading to apoptosis induced through serum 
deprivation is under debate, it is believed that components o f both the intrinsic and 
extrinsic apoptosis pathway may be involved. One consequence o f  sem m  deprivation is
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the inactivation o f cAMP-dependent protein kinase (protein kinase A, PKA) which is 
responsible for proper regulation o f numerous cell pathways, including but not limited to 
glycogen synthesis and breakdown, glycolysis, DNA condensation (Huang, N  et al., 
2001). In addition, the elimination o f necessary growth factors such as IL -3 , which 
normally stimulates the phosphorylation and inactivation o f Bad (a pro-apoptotic member 
of the Bcl-2 family) also plays a role. In its phosphorylated form Bad is rendered 
inactive and cannot heterodimerize with B c1-Xl, an anti-apoptotic m em ber o f the Bcl-2 
family (Zha, J et al., 1 9 9 6 ), resulting in cell survival. Absence o f  IL -3  during serum 
deprivation prevents Bad phosphorylation, allowing it to interact and inhibit the anti- 
apoptotic function o f B c1-X l, resulting in apoptosis. This can be further aggravated by 
presence o f Bax which has also been shown to interact with m ultiple anti-apoptotic 
proteins including B c1-Xl (Sattler, M et al., 1 9 9 7 ).
In a more resent study by Charles et al. 2005, serum deprivation was associated 
with the increase in Bax expression and decrease in Bcl-2 expression, which leads to the 
induction o f apoptosis (Charles, I et al., 2005). However, unlike the intrinsic apoptosis 
pathway in which Bax seems to play a central role, other factors m ust also be taken into 
account in serum deprivation. Another factor leading to apoptosis through serum 
deprivation is activation o f caspase 8 which is independent of the mitochondrial and Bax 
associated cell death pathway (Akihiro, H et al., 2006).
Therefore, by inhibiting Bax activity, anti-Bax intrabodies can maintain strong 
cell viabilities 24h following serum deprivation, however this effect is overwhelmed by 
other cellular process such as caspase 8 activation, whose expression is reported to 
increase after 72hrs in cells undergoing serum deprivation.
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5.1 Elucidation of possible binding site for anti-Bax VhHs
Bax permealization of the outer mitochondrial membrane (OMM) has been shown 
to occur through the formation of the permeability transition pore (PTP) when Bax binds 
to the MOM component o f the PTP, VDAC (Narita, M et al., 1998). Since mitochondria 
membrane potential was not destroyed in cells expressing the anti-Bax intrabodies 
following oxidative stress, we believed that the Bax-VDAC interaction may be prevented 
in these cells. This theory was tested by comparing the level o f Bax which is co­
precipitated with VDAC in control (non-transfected) and anti-Bax VhH expressing cells. 
We showed that the level of Bax binding to VDAC was indeed decreased in the 
transfected cells, which suggests that the antibodies may be binding to the VDAC binding 
site on Bax (specifically the transmembrane, a9 helix). However, since the level of 
expression of the anti-Bax intrabodies is not known, we plan to retest this theory using 
anti-Bax single domain antibodies and recombinant Bax {in vitro).
Due to the strong similarities in all Bcl-2 type proteins, we cannot eliminate the 
possibility that the anti-Bax VhH may also be binding to other Bcl-2 type proteins. The 
intrinsic apoptosis pathway is regulated by the pro- and anti-apoptotic members of the 
Bcl-2 family. Specifically, a major determining factor for induction o f apoptosis is the 
change in the ratio between these protein groups. Therefore if, we limit the activity of 
pro-apoptotic proteins such as Bax, the ratio will shift in favour o f the anti-apoptotic 
proteins, resulting in inhibition of apoptosis as seen in cells expressing the anti-Bax 
intrabodies. If the intrabodies also inhibited the anti-apoptotic Bcl-2 proteins, this ratio 
would not be affected, and we would then see no major change in cell viabilities 
compared to the treated/non-transfected cells. Since this effect was not seen, this
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suggests that the anti-Bax intrabodies are probably not functionally interfering with the 
activity o f the anti-apoptotic Bcl-2 type proteins.
Finally, due to the functional redundancy o f pro-apoptotic members of the Bcl-2 
family, specifically Bax and Bak it is possible that the intrabodies are binding to common 
sites such as the BH3 domain (which is inaccessible in anti-apoptotic Bcl-2 type 
proteins), thereby preventing dimerization and subsequent activation o f these proteins.
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Chapter 6: Conclusions & Future Work
In this study we have identified several non-toxic, VhH clones which have be 
identified for their ability to bind recombinant Bax specifically. Through in vitro studies 
involving direct Bax induced MOMP, (characterized by increased ROS) these antibodies 
exhibited potential to both bind and more importantly inhibit Bax function, thereby 
limiting mitochondrial damage brought on by this pro-apoptotic protein. In addition 
when these V hH s were expressed intracellularly, as intrabodies, they rendered their host 
cells resistant to oxidative-stress-induced apoptosis, by preventing the Bax 
permealization o f the mitochondria (during oxidative stress).
This work has important implication for studying cellular mechanisms in vivo, by 
phenotypically inhibiting protein functions. Although, protein inhibition at the mRNA 
level, through RNAi, is a common means to study protein functions, intrabodies against 
specific intracellular targets may offer greater precision and feasibility, since they can be 
designed to target specific components o f a particular protein of interest.
In order to determine how the anti-Bax VhHs inhibit Bax activity, it would be 
important to further confirm their ability to bind on the VDAC site o f Bax (the 
transmembrane c-terminus, a9). In addition it would also be useful to identify other 
proteins which may be interacting with the anti-Bax V hH s. This can be accomplished by 
carrying out an immunoprecipitation assay using anti-GFP bound to protein-G linked 
sepharose, since the anti-Bax intrabodies are expressed in fusion with GFP. Any proteins 
in addition to Bax which may be interacting with the anti-bax intabodies can then be 
further analyzed and identified through mass spectroscopy.
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In addition this work also opens new opportunities for treating neurodegenerative 
diseases which involve cell death induced by oxidative stress and Bax activation. Beside 
their direct use as intrabodies in the context o f gene therapy, the present V hH s can also be 
used as models to identify specific and non-toxic small molecular weight inhibitors of 
Bax from commercially available pharmacophore libraries.
The application o f the anti-bax intrabodies as direct therapeutic agents against 
neurodegenerative diseases is limited largely by the difficulty in crossing the blood brain 
barrier. As a result a future goal is to use one o f the more efficient VhH (5-2), which has 
shown strong anti-Bax activity both in vitro and in vivo, as a model for identifying a 
small chemical compound. This chemical compound can be selected from a 
pharmacophore library for its ability to compete for the binding of Bax in vitro.
Specifically, a binding assay can be carried out using radiolabeled (C14) VhH 
bound to recombinant Bax. The pharmacophore library can be screened to identify a 
chemical which can competitively disrupt this interaction by binding at the same site on 
Bax as the VhH. In this way a low molecular weight mimic of the VhH can be identified 
which will be more likely to cross the tightly regulated blood brain barrier in order to 
prevent oxidative stress induced apoptosis. In addition, as opposed to gene therapy, by 
using a chemical compound the administration level (frequency and dosage) can be 
properly controlled to prevent any possibility of uncontrolled cell growth leading to 
cancer.
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